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Table 1: Abbreviations 
Abbreviation Full spelling 
ABS Antibiotic Stewardship 
AMR Antimicrobial resistance 
BC Blood culture 
BSI Bloodstream infection 
BW Body weight 
CA Community-acquired 
CA-BSI Catheter-associated bloodstream infection 
CLABSI Central line-associated bloodstream 
infection 
CAP Community-acquired pneumonia 
CC Clonal Complex 
CIE Cefazolin inoculum effect 
CLABSI Central-line associated bloodstream 
infection 
CSF Cerebrospinal fluid 
CVC Central venous catheter 
CZO* Cefazolin 
d Days 
DTP Differential time to positivity 
FLU* Flucloxacillin 
FUBC Follow-up blood cultures 
GFR Glomerular filtration rate 
HA Hospital-acquired 
HAP Hospital-acquired pneumonia 
HCA Healthcare-associated 
ICU Intensive care unit 
IQR Interquartile range 
MRSA Methicillin-resistant Staphylococcus aureus 
MSSA Methicillin-susceptible Staphylococcus 
aureus 
PET Positron emission tomography 
S. aureus Staphylococcus aureus 
SAB Staphylococcus aureus bacteraemia 
SAPS score Simplified Acute Physiology Score 
SOFA score Sepsis-related Organ Failure Assessment 
score 
Spa Staphylococcus aureus protein A 
SSI Surgical site infections 
SSTI Skin and soft tissue infections 
TEE Transoesophageal echocardiography 
TTE Transthoracic echocardiography 
UTI Urinary tract infection 
 





1. Introduction  
Staphylococcus (S.) aureus is a Gram-positive widespread pathogen, which can temporarily colonize 
the mucous membranes of the nose and throat and the skin in intertriginous areas. Due to its vast 
variety of expressed virulence factors, it is the most common causative of community-acquired skin 
and soft tissue infections, but also one of the most frequently cultured pathogens in nosocomial 
infections including surgical site infections (ECDC 2019; Annual Epidemiological Report for 2017; 
Healthcare-associated infections: surgical site infections), catheter-associated bloodstream infections 
(ECDC 2019; Annual epidemiological report for 2017. Healthcare-associated infections acquired in 
intensive care units) and ICU-acquired pneumonia (ECDC 2018; Incidence and attributable mortality 
of healthcare-associated infections in intensive care units in Europe, 2008-2012). Once gaining access 
to the circulation, it can spread and cause several complications including septic shock syndrome, 
metastatic abscesses in deep tissues, spondylodiscitis, atypical late implant infections, and infective 
endocarditis. Up to 10% of cases are known to relapse (recurrence or reinfection) with the highest 
risk in haemodialysis patients (Choi et al. 2020). Persistent bacteraemia is a common manifestation 
of S. aureus bacteraemia (SAB) and occurs in 6% -38% of infection episodes, being more likely to 
occur in MRSA infections due to the probably lower efficiency of Vancomycin compared to ß-lactams 
in terms of bloodstream clearance or a different subset of virulence factors (Van Hal, Jensen, and 
Vaska 2012). 
2. Incidence 
Exact incidences of SAB are difficult to ascertain due to the lack of population-based prospective 
surveillance studies. Data from countries with nationwide surveillance of SAB indicate an incidence 
range between 26/100,000 population (Scandinavian countries) to 50/100,000 population, being 
higher in countries with a high burden of Methicillin-resistant S. aureus (MRSA). Incidences rise with 
age, being lowest in the paediatric population. Known risk factors associated with a higher incidence 
are male gender, dependence on haemodialysis, and community-acquired bacteraemia (Van Hal, 
Jensen, and Vaska 2012). 
3. Case fatality rates 
Published case fatality rates vary greatly and highly depend on age, comorbidities, and clinical 
manifestations, and range between 10% and 30% (Van Hal, Jensen, and Vaska 2012). The SAB 30-day 
all-cause mortality rate results in approximately 2 to 10 deaths annually per 100,000 population. 
Elderly patients (>75 years of age) have an overall twofold higher 7-day and 30-day mortality than 
younger adults (Bassetti et al. 2018; Van Hal, Jensen, and Vaska 2012). Septic shock and bacteraemia 
originating from the lung are associated with higher mortality (Conterno, Wey, and Castelo 1998). 
Certain comorbidities have been found to influence SAB mortality, including the presence of 
alcoholism, immunosuppression, cirrhosis, congestive cardiac failure, malignancy, chronic renal 
failure requiring haemodialysis, and the presence of multiple comorbidities (Van Hal, Jensen, and 
Vaska 2012). The setting of SAB (HA-SAB or CA-SAB) seems not to affect the 30-day-mortality (Van 
Hal, Jensen, and Vaska 2012).  
4. Treatment 
Since the 1970s, narrow-spectrum cephalosporins such as Cefazolin and antistaphylococcal penicillins 
such as Flucloxacillin are the mainstay of treatment in MSSA-SAB. Cefazolin quickly became a 
preferred choice due to its efficacy, excellent safety profile, favourable administration schedule, and 
low costs. However, soon treatment failures in deep-seated (e.g., endocarditis, spondylodiscitis) and 
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high-inoculum infections (e.g., catheter-associated bloodstream infection) have been reported. This 
failure was reproduced in vitro by demonstration of a marked inoculum effect in certain strains 
(cefazolin inoculum effect, CIE). This effect is characterized by susceptible MIC values in testing 
systems working with the standard inoculum (~5x105 CFU/mL) with a pronounced increase in MIC 
(>16 µg/mL) when tested with a higher inoculum (5x107 or greater). This effect originates from the 
presence of a staphylococcal ß-lactamase encoded by the blaZ gene. Certain isotypes of this ß-
lactamase, namely types A and C, have been linked to the CIE. Inactivation or deletion of blaZ or 
addition of a ß-lactamase-inhibitor reverse this phenomenon. Presence of the CIE was detected in 
15-40% of the infecting S.aureus strains with a regional variation in prevalence (K-H Song et al. 2017). 
In strains where CIE was proven in vitro, outcomes of patients were poorer when treated with 
Cefazolin compared to patients whose strains did not exhibit CIE (Miller et al. 2018, S. Lee et al. 
2018). On the other side, this inoculum effect has been proposed as a cause for poorer clinical 
outcomes in patients receiving a β-lactam-β-lactamase inhibitor formulation as well (Beganovic et al., 
2019, Paul et al. 2011). In high-inoculum infections, the fixed proportion of added ß-lactamase-
inhibitor is probably not sufficient in inactivating the produced ß-lactamases at the site of infection. 
This phenomenon does not occur with antistaphylococcal penicillins like Flucloxacillin or Nafcillin. 
However, Flucloxacillin has some unfavourable side effects like nephro- and hepatotoxicity and has 
to be administered six times daily. A 2018 systematic review and meta-analysis evaluated ten 
observational studies to assess the efficacy and safety of the two regimens.  The results indicated 
that compared to antistaphylococcal penicillins, cefazolin was associated with a significant reduction 
in mortality and clinical failure without increasing the recurrence of bacteraemia and exhibited 
significantly lower nephrotoxicity and hepatotoxicity (Shi et al. 2018). Due to the lack of prospective, 
adequately powered randomized controlled trials, there is still ongoing discussion about which drug 
to prefer as results from narrative reviews and observational studies are conflicting. Data on 
comparative efficacies between ß-lactams and other classes of drugs and between other classes of 
drugs are scarce and usually refer to MRSA-bacteraemia. 
5. Antibiotic Stewardship and care bundles 
Often during the first episode of S. aureus bacteraemia (SAB) it is unclear whether this is an episode 
of transient uncomplicated bacteraemia, whether this episode will lead to one or more of the 
complications mentioned above or whether the patient already has one of those complications. 
Generally spoken, isolation of S. aureus from the bloodstream should not be considered 
contamination unless underlying causes have been excluded. In complications like infective 
endocarditis or spondylodiscitis, the human immune system is powerless in controlling the infection, 
thus a rapid surgical intervention is key to improve patient outcomes. Additionally, a rapid initiation 
and appropriate duration of a proper antibiotic treatment and identification of the focus of 
bacteraemia are crucial to improve patient outcomes. Although due to its complexity SAB nowadays 
is considered a distinct disease entity not comparable to bloodstream infection caused by other 
bacteria, many physicians are not aware of the fact itself as well as about the cornerstones of 
management. To ensure proper workup and reduce treatment failure and mortality, infectious 
disease consultations (Brigg Turner et al. 2016) or real-time antimicrobial stewardship pharmacist or 
medical microbiologist consultations have been proposed and have proven to be effective in 
improving adherence to the SAB bundle (Arensman et al. 2020). Even though international guidelines 
on MSSA-bacteraemia are still lacking (projected publication IDSA: fall 2020), there are some precise 
national or online guidance documents (e.g., “Staphylococcus aureus Bacteraemia (SAB) 





6. The Staphylococcus aureus bacteraemia care bundle 
Care bundles in infection prevention and control “include a set of evidence-based measures that, 
when implemented together, have shown to improve patient care and have a greater impact than 
that of the isolated implementation of individual measures” (“Bundles in Infection Prevention and 
Safety - ISID”). 
The Staphylococcus aureus bacteraemia (SAB) care bundle is presented as a checklist here to give a 
summary of the cornerstones of workup in patients with an episode of SAB (Figure 1). 
 
 
Figure 1: The SAB care bundle 
 
*BW=Body Weight  
Dosages are given without consideration of renal and hepatic function and total body weight and in 





Briefly, evidence-based, internationally accepted cornerstones include: 
At initiation of therapy:  
□ Diagnosis and removal or drainage of foci 
□ MSSA: Start treatment with Cefazolin or Flucloxacillin 
□ MRSA: Continue or start treatment with Vancomycin (loading dose!) 
□ In concomitant implant infections combination with Rifampicin 1 x 900mg 
After initiation of therapy: 
□ Perform TTE/ TEE in all patients 
□ Follow-up blood cultures to document effective bloodstream clearance 
□ Clinical re-evaluation 3-5 days after initiation of therapy 
□ Detection of metastatic complications (MRT/ FDG/PET-CT) 
□ Overall duration of therapy:  
o min. 14 days after first negative blood culture (uncomplicated course*) 
o min. 4-6 weeks (complicated course) 
*No Infective endocarditis, no implanted devices, follow-up blood cultures sterile 2-4 days after 




Our study aimed to evaluate the adherence to the SAB bundle and to assess whether proper 
adherence improved patient survival. Duration of treatment and the drug chosen for treatment were 
of specific interest. Furthermore, we wanted to assess clinical outcomes, the mode of acquisition and 
whether nosocomial transmissions took place. As data for spa type distributions in MSSA-SAB are 




1. Population and study design 
The University Hospital of Leipzig is a 1451-bed tertiary academic hospital. Patient charts were 
evaluated retrospectively using information from electronic health records. Participants were 
included only once during the first SAB episode, in patients with available follow-up isolates all 
strains were submitted to spa typing. Baseline characteristics, clinical presentation, treatment, and 
clinical outcomes were assessed. Written consent was not required due to the retrospective nature 
of the study.  
During the study period, infectious diseases specialist consultation was available, but optional and 
not activated routinely. Antibiotic stewardship ward rounds were established providing visitation of 
the 6 ICUs (paediatric, internal, three anaesthesiology units, neurologic ICU), the septic surgery 
department, the transplantation unit, the neonatology ward, and two pneumology wards. The ward 
rounds took place once weekly with the ABS team consisting of a medical microbiologist, a clinical 
pharmacist, and an infectious diseases specialist. During ward rounds, all patients receiving 
antibiotics were evaluated with the treating physician. Independently, every SAB diagnosed in the 
medical microbiology laboratory was communicated via phone to the treating physician. Key 
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components of the SAB bundle were communicated during the call and summarized in the laboratory 
report.  
2. Microbiology 
From June 2017 to June 2019, 378 S. aureus strains (291 primary and 87 follow-up isolates) were 
prospectively collected from blood cultures (BacT/ALERT®, BioMérieux, Nürtingen, Germany) and 
stored at - 80°C in cryopreservation stocks (Cryobank™, Mast Diagnostica GmbH, Reinfeld, Germany) 
for further analysis. Identification was conducted by VITEK® MALDI-ToF MS (BioMérieux, Nürtingen, 
Germany). Determination of antibiotic susceptibility was performed with microbroth dilution method 
according to the International Standard ISO 20776-1 with plates manufactured in-house. Antibiotics 
tested are summarized in Table 2. EUCAST breakpoints were applied, plates were read with the 
Micronaut Skan device (Thermo Scientific™, Schwerte, Germany). Penicillinase production in 
Penicillin-susceptible strains was not investigated phenotypically with disc diffusion and edge-
reading, as recommended by EUCAST (Eucast.Org/Clinical_breakpoints). MLSB phenotypes were 
further characterized with a double-disc diffusion test (D-Test) as described elsewhere (Wayne 2011). 
MRSA resistance was confirmed with both performance of a molecular test (Cepheid GeneXpert® 
MRSA, Cepheid Europe SAS, 81470 Maurens-Scopont, France) and detection of PBP2a with the Abbot 
CLEARVIEW™ PBP2a SA Culture Colony Test (Alere, Scarborough, USA). In MRSA strains, presence of 
PVL was investigated with detection of lukS-PV with LightMix® Modular CA-MRSA (TIB MOLBIOL 
GmbH, Berlin, Germany). 
Table 2: Antibiotics tested in the Gram-positive panel 
Abbreviation* Antibiotic Abbreviation* Antibiotic 
BEN Benzylpenicillin CIP Ciprofloxacin 
OXA Oxacillin MOX Moxifloxacin 
AMS Ampicillin/ Sulbactam LEV Levofloxacin 
PIT Piperacillin/ Tazobactam ROX Roxithromycin 
CUR Cefuroxime CLI Clindamycin 
CTA Cefotaxime DOX Doxycycline 
IPI Imipenem TIG Tigecycline 
MER Meropenem RIF Rifampicin 
GEN Gentamicin VAN Vancomycin 
AMI Amikacin TEI Teicoplanin 
TOB Tobramycin LIN Linezolid 
FOS Fosfomycin DAP Daptomycin 
TRS Trimethoprim-Sulfamethoxazole 
*EUCAST abbreviation system 
 
3. Spa Typing and Whole Genome Sequencing 
Molecular typing methods were performed at the National Reference Centre for Staphylococci and 
Enterococci (Robert-Koch-Institute) by Franziska Layer, PhD in Wernigerode, Germany.  
Strains were grown overnight in tryptic soy broth at 37°C. DNA was extracted using the DNeasy tissue 
kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions with the modification 
that lysostaphin (100 mg/L; Sigma, Munich, Germany) was added to the cell-lysis step.  
For spa typing amplification and sequencing of the polymorphic X-region of the protein A gene (spa) 
was performed as described elsewhere (Harmsen et al. 2003; Strommenger et al. 2008). Spa types 
were grouped into spa clonal complexes (spa CC) using the BURP (Based Upon Repeat Pattern) 
algorithm (Mellmann et al. 2008) of the Ridom Staphtype Software (version 2.2.1, Ridom GmbH, 
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Würzburg, Germany). BURP default parameters were set as described by Mellmann et al. Spa types 
shorter than five repeats were excluded from the analysis due to their limited information content. 
To investigate clonal nosocomial transmission, isolates from hospital-acquired SAB were checked for 
similarity in spa type and preferably, but not exclusively with the same phenotypic resistance pattern 
with a temporal overlap within an arbitrary time frame of 3 months. CgMLST based on 1489 genes of 
the S.aureus core genome was performed for those strains. DNA quantification was carried out using 
the Qubit dsDNA HS Assay Kit (Invitrogen/Thermo Fisher Scientific, Karlsruhe, Germany). A total of 
1 ng of extracted DNA was employed for library preparation using the Nextera XT DNA library prep 
kit according to the manufacturer’s instructions (Illumina, San Diego, CA). Sequencing was performed 
on an Illumina NextSeq platform in paired-end mode with a final readout of 2 × 150 bp. Quality of 
raw read data was assessed by an in-house-developed pipeline (QCumber-2). 
For genome assembly and core-genome multilocus sequence typing raw read files were imported 
into Ridom SeqSphere+ version 7.2.0 (Ridom GmbH, Münster, Germany) (Jünemann et al. 2013) and 
assembled de novo by using SPAdes (version 3.11.1) (Bankevich et al. 2012), default settings, 
integrated in the linux version of SeqSphere). The S. aureus cgMLST scheme version 1.3 (Leopold et 
al. 2014) (implemented in SeqSphere+) was applied, resulting in a complex type (CT) for each isolate. 
Furthermore, a minimum spanning tree was calculated in SeqSphere+ based on cgMLST analysis. To 
detect closely related isolates, the threshold for cluster distance determination was set to 10 cgMLST 
alleles. 
4. Definitions 
SAB was defined as the presence of S. aureus in at least one blood culture bottle. Onset of SAB was 
marked by the sampling date of the first positive blood culture.  
SAB was classified as hospital-acquired with the first positive blood culture drawn ≥72 hours after 
admission, either in our hospital or during a directly preceding stay in an external hospital of a min. 
of ≥72 hours duration. HCA infections were defined as positive blood cultures taken within 72 hours 
of admission, with one or more of the following risk factors present: Hospitalization or surgery within 
6 months prior to admission, or dependence on haemodialysis. Otherwise, SAB was classified as 
community-acquired.  
Follow-up blood cultures (FUBC) were defined as (1) the first pair sampled within 14 days after the 
index blood culture, (2) with no more than three days apart from each other if no therapy was 
initiated or (3) every BC sampled between one day after initiation of antibiotic treatment until the 
cessation of therapy.  
Therapy was considered empiric if no pathogen was cultured on initiation of treatment and no 
results of susceptibility testing were available.  
A primary focus for SAB was codified only when there was clinical evidence of a source plus a 
cultured sample from the presumptive site of infection yielding growth of S. aureus. Sources of SAB 
were divided into primary sources (SSTI, catheter-related SAB, pneumonia, urological focus, early SSI) 
and secondary sources manifesting after initial haematogenous spread (IE, spondylodiscitis, late 
haematogenous SSI). Secondary sources thus were classified as complications. 
Central-line associated bloodstream infection was recorded following ECDC criteria for CRI3-CVC: 
Bloodstream infection occurring 48 hours before/ after CVC removal AND positive S. aureus culture 
from the catheter tip (semi-quantitative, >15 CFU) AND/ OR CVC blood culture positive >=2 hours 
before the peripheral blood culture. In defining surgical site infections (SSI) ECDC case definitions 
were applied (ECDC 2017). 
Assessed hospital metrics included the length of stay (LOS), initial admission to ICU, all-cause 
14-, 30- and 90-days-mortality, days to death, days to readmission, LOS on readmission and 
readmission to ICU. Previous hospitalization in the preceding 6 months (duration >3 days) was 
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documented. Due to lacking access to precise data, previous antibiotic therapy was not evaluated. 
Clinical endpoints included uncomplicated SAB (no septic shock, no secondary focus, favourable 
clinical course), and registration of complications. 
A relapse was assumed in a new episode of SAB after a subsequent set of negative blood cultures, 
not differentiating between recurrence and reinfection. 
For assessment of bundle adherence, constituents of the bundle believed to have a major impact 
upon survival or being of diagnostic and prognostic value were extracted.  
Those core components included: 
• Initiation of Cefazolin or Flucloxacillin in MSSA-SAB (administration for at least 3 days) 
• Initiation of Vancomycin or Daptomycin in MRSA-SAB 
• Performing FUBC for diagnostic purposes and calculation of therapy duration 
• Exclusion of an infectious endocarditis with a TTE and/ or TEE as a minimum of secondary 
focus exclusion 
• Administration of 16-30 days of an effective antibiotic treatment from a microbiological point 
of view (in vitro susceptibility and conclusive PK/PD properties of the drug used in patients 
with combination therapy or switch from FLU/ CZO) 
 
Source control was not included, as in patients with an eradicable focus surgery or drainage were 
performed consistently.  
  
Dosing of Cefazolin and Flucloxacillin was assessed. Proper dosing was assumed with 4-6x2g 
Flucloxacillin in normal renal function and reduction to 4x2g in GFR 8-18 ml/min., 3x2g in GFR 2-8 
ml/min. and 3x2g in haemodialysis patients. Cefazolin was considered properly dosed with 3-4x2g in 
normal renal function with reduction to 3-4x1g in GFR 10-29 ml/ min, 2x1g in GFR < 10ml/ min. In 
haemodialysis patients, a dosage of 2x0.5g on non-haemodialysis days and 1x1.5g on haemodialysis 
days (administration after haemodialysis) was considered sufficient. Targeted antibiotic therapy 
other than the aforementioned substances was not assessed in detail; often regimens were switched 
multiple times during one treatment course, thus not allowing for a clear comparison of homogenous 
treatment protocols. Therefore, the treatment with Flucloxacillin or Cefazolin was compared to any 
other regimen consisting of one or more substances, mirroring the treatment reality in our hospital 
setting.  
 
5. Statistical analysis 
For continuous data, median with interquartile range was reported. Categorical variables were 
reported as frequency distributions and, when suitable, as total numbers with relative frequency 
distributions. The influence of categorical variables on survival was assessed with Kaplan-Meier curve 
modelling and difference between groups evaluated with log rank tests. Hazard ratios for categorical 
and continuous variables were calculated with Cox regression modelling. Presence of normal 
distribution of values was assessed with normal Q-Q- plots. Means between independent groups 
were compared with t-test or Mann Whitney, if suitable. Associations between categorical variables 
was assessed with Pearson Chi-Square test or two-tailed Fisher`s Exact test, when appropriate. In 
post-hoc analysis of statistically significant results in Chi-Square tests including more than 2x2 
variables significance levels were corrected using the Bonferroni correction for multiple tests. Tests 
were two-tailed with statistical significance defined with a p-value <0.05. Statistical analyses were 





1. Participant baseline characteristics and risk factors for SAB 
From June 2017 to June 2019, 291 cases were included in the analysis. Patients were followed up 
until 01.01.2020. A cumulative number of 68,336 patient days were available for analysis. 
Table 3 gives an overview of baseline patient characteristics, comorbidities, and additional risk 
factors known to be associated with SAB.  
Patients who received Cefazolin/ Flucloxacillin as targeted treatment and those who received any 
other antibiotic therapy were compared regarding comorbidities and risk factors.  As our data 
seemed balanced and total sample size was relatively small, we decided not to use propensity score 
matching before comparing outcomes of the groups. 
Median age of our cohort was 67 years (IQR 56-78), 63.9% were male.  
63.9% of patients had been hospitalized during the previous 6 months (duration of stay >3 days). 
29.6% were overweight (BMI 25-29), 25.8% were obese in 1st to 3rd grade (BMI 30->40). 42.6% 
presented with stages 3-5 of chronic renal failure. 8.6% of patients were dependant on 
haemodialysis. As expected in a population with this age distribution, many patients had underlying 
chronic illnesses, e.g., diabetes mellitus (49.5%), congestive heart failure (45.7%), atrial fibrillation 
(37.8%), and presented with chronic wounds or ulcers (34.7%). Nicotine and alcohol abuse were 
documented for 15.5% and 14.8% of patients. 18.6% had an underlying malignancy. 16.2% received 
immunosuppressive therapy, 2.7% were transplant recipients. 
29.9% of patients underwent surgery in the preceding 6 months, most frequently abdominal (4.5%), 
spine (4.1%) and vascular (4.1%) surgery and device implantations (3.1%). 28.7% of patients who 
underwent surgery developed a surgical site infection. 
Roughly a third of patients (33.6%) had a central venous catheter in place before developing a SAB 
with a median of 7 days (IQR 4-38.25) before onset of SAB. The amount of cumulative central-line 
days was 5,101. 
39.5% of patients were initially admitted to ICU, 22.8% of them after emergency surgery. Median 
SAPS and SOFA scores were 42 (IQR 32-54.5) and 5 (IQR 2-10), respectively. 24.7% of patients 




Table 3: Participant characteristics and risk factors for SAB 
Missing information on antibiotic treatment for five patients (included in “Total”).  
Numbers in columns and rows do not sum up to 291 patients due to missing information. 
 









Age (y), median (IQR) 67 (56-78) 68 (57-79) 67 (54-78) 66 (45-77) 
Age >65, n (%) 169 (58.1) 86 (59.3) 68 (57.1) 12 (54.5) 
Length of stay, median (IQR) 23 (13-36) 25 (16-37) 20 (11-32) 17 (4-45) 
Patient days (inclusion 
period plus follow-up time) 
68,336    
Male 186 (63.9) 97 (66.9) 70 (58.8) 15 (68.2) 
     
Obesity, classification  
based on BMI (kg/m²): 
    
Normal = BMI 18,5-25 103 (35.4) 58 (40) 35 (29.4) 9 (40.9) 
Grade 1 = BMI 30-34,9 37 (12.7) 18 (12.4) 17 (14.3) 2 (9.1) 
Grade 2 = BMI 35-39,9 13 (4.5) 6 (4.1) 5 (4.2) 2 (9.1) 
Grade 3 = BMI >= 40 25 (8.6) 9 (6.2) 14 (11.8) 2 (9.1) 
Overweight = BMI 25-29,9 86 (29.6) 47 (32.4) 32 (26.9) 3 (16.7) 
Underweight = BMI<18,5 14 (4.8) 4 (2.8) 8 (6.7) 2 (9.1) 
     
Nicotine abuse 45 (15.5) 26 (17.9) 16 (13.4) 2 (9.1) 
Alcohole abuse 43 (14.8) 23 (15.9) 19 (16.0) 1 (4.5) 
Undelying malignancy 54 (18.6) 22 (15.2) 22 (18.5) 9 (40.9) 
     
Chronic renal failure 
(KDIGO): 
    
Normal renal function 126 (43.3) 56 (38.6) 58 (48.7) 10 (45.5) 
Stage 1 = GFR 90 5 (1.7) 3 (2.1) 2 (1.7) - 
Stage 2 = GFR 60-89 32 (11) 18 (12.4) 13 (10.9) - 
Stage 3 = GFR 30-59 76 (26.1) 39 (26.9) 27 (22.7) 9 (40.9) 
Stage 4 = GFR 15-29 23 (7.9) 10 (6.9) 12 (10.1) - 
Stage 5 = GFR <15 25 (8.6) 17 (11.7) 6 (5.0) 2 (9.1) 
Hemodialysis dependance 25 (8.6) 17 (11.7) 6 (5.0) 2 (9.1) 
     
Chronic liver disease 45 (15.5) 23 (15.9) 20 (16.8) 1 (4.5) 
Pancreatitis 13 (4.5) 6 (4.1) 6 (5.0) 1 (4.5) 
Asthma requiring 
corticosteroids 
5 (1.7) 1 (0.7) 3 (2.5) - 
 
Diabetes mellitus 144 (49.5) 76 (52.4) 56 (47.1) 9 (40.9) 
Atrial fibirllation 110 (37.8) 56 (38.6) 46 (38.7) 6 (27.3) 
Peripheral Arterial Disease 68 (23.4) 27 (22.7) 35 (24.1) 3 (13.6) 
Hypertonia 206 (70.8) 104 (71.7) 83 (69.7) 15 (68.2) 
Coronary heart disease 80 (27.5)    
Congestive heart failure 133 (45.7) 70 (48.3) 49 (41.2) 5 (22.7) 
COPD 48 (16.5)    
Decubital ulcus/ chronic 
wound 
101 (34.7) 53 (36.6) 41 (34.5) 5 (22.7) 
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Intravenous drug abuse 11 (3.8) 3 (2.1) 7 (5.9) 1 (4.5) 
Immunosuppression 
including Corticosteroids 
47 (16.2) 19 (13.1) 21 (17.6) 7 (31.8) 
Organ Transplant recipient 8 (2.7) 3 (2.1) 5 (4.2)  
     
Treatment on ICU at onset  149 (51.2) 70 (48.3) 63 (52.9) 12 (54.5) 
of SAB     
Requiring catecholamines 72 (24.7) 31 (21.4) 33 (27.7) 5 (22.7) 
SOFA score (ICU), 
assessment of morbidity, 
median (IQR) 
5 (2-10) 4 (2-9) 5 (2-11) 7 (4-9) 
SAPS score (ICU), assessment 
of mortality, median (IQR) 
42 (32-54.5) 42 (32-58) 40 (32-53) 49 (33-54) 
qSOFA >2 (ICU and non-ICU) 77 (26.5) 35 (24.1) 31 (26.1) 9 (40.9) 
Central venous line before 
onset of SAB 
81 (27.8) 31 (21.4) 35 (29.4) 13 (59.1) 
  




Cumulative central-line days (d) 5,101 
Previous hospitalization in last 6 months  
(duration >3 days) 
186 (63.9)   
Initial admission to ICU 115 (39.5)   
Postoperative admission to ICU  34 (22.8) 
   
Additional risk factors  n (%) Relative % 
Surgical procedures in the preceding 6 months 87 (29.9) 100 
Type of surgery performed:    
Abdominal  13 (4.5) 14.9 
Spine  12 (4.1) 13.8 
Vascular  12 (4.1) 13.8 
Device implantation  9 (3.1) 10.3 
Wound  8 (2.7) 9.2 
Brain  6 (2.1) 6.9 
Heart  6 (2.1) 6.9 
Thoracic  6 (2.1) 6.9 
Fracture  4 (1.4) 4.6 
Amputation  4 (1.4) 4.6 
Urinary tract  3 (1) 3.4 
Cancer  3 (1) 3.4 
Teeth  1 (0.3) 1.1 
Postoperative wound infection 25 (8.5) 28.7 




2. Outcomes: hospital metrics and clinical outcomes 
Clinical and hospital outcomes of all patients were assessed. From 291 patients, 79 patients (27.14%) 
had an uncomplicated episode of bacteraemia only. 212 patients (72.85%) had at least one 
complication. The latter group was divided into those with one complication (44.3%), two 
complications (17.5%), three complications (8.2%) and four complications (2.4%). The distribution of 
complication present in each group is shown in Figure 2, the distribution of complication overall is 
depicted in Figure 3. 
 
Figure 2: Distribution of complications depending on cumulative number of complications 
 
 
Figure 3: Distribution of clinical outcomes 
Leading complications were sepsis (56.7%), implant infection (12.7%) and spondylodiscitis (12.4%). 
Infective endocarditis occurred in 8.9% of cases, followed by osteomyelitis (8.6%), persistent 
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bacteraemia (4.8%), intraspinal abscess (4.5%), and haematogenous spread (4.1%). 41.6% developed 
an acute kidney failure, 13.4% an acute liver failure. 
94 deaths (32.3%) occurred during available follow-up time. In 68,336 patient-days (pd) during 
inclusion period and follow-up, Incidence density rate for 30-days mortality was 0.96/ 1,000 pd, 
incidence density rate for 90-days mortality was 1.14/ 1,000 pd. 
Median time to death was 12 days (IQR 4-26.25). Consistently, early death (0-14 days after SAB) was 
predominant and occurred in 48 patients (16.5%). Intermediate death (14-30 days) occurred in 19 
(6.5%), late death (30-90 days) in 12 (4.1%) and death later than 90 days in 15 patients (5.2%). Means 
of age were significantly higher in the early death group (75.8 y) compared to the late death group 
(62.2 y, p=0,035) and death later than 90 days (61.8 y, p=0.013). 30-days-and 90-days mortality was 
lower in patients with CA-SAB compared to HCA- and HA-SAB, although the difference was not 
statistically significant (p30 days=0,093, p90 days=0,086). Patients with sepsis had a significantly 
higher 14-, 30- and 90- days mortality compared with patients without sepsis (p<0.001). As 
previously described (Bassetti et al. 2018), mortality was higher in elderly patients. Age >65 years 
significantly increased 30- and 90-days mortality (p=0.001). 
Median length of stay (LOS) was 23 days (IQR 13-36). 37.8% of patients were readmitted in a median 
of 52 days (IQR 15-135), from those readmitted 14.5% were readmitted to ICU. The length of stay at 
readmission was a median of 11 days (IQR 4-21.5). 
Table 4 gives a characterization of early, intermediate, and late death according to the underlying 
complications. In 25% of patients in the late death group (30-90 days after first SAB episode), 
persistent bacteraemia was present. Besides that, there was no statistically significant association 
between distinct complications and early, intermediate or late death. Table 5 gives an overview over 
assessed hospital metrics and clinical outcomes. 
As there was an overlap between complication groups (28.6% of patients developed more than one 
complication), a surrogate parameter of cumulative number of complications was introduced. 
 
Table 4: Association of complication with time to death  







Sepsis; n (%) 40 (85.1) 17 (89.5) 11(91.7) 0.78 
Infective endocarditis, n (%) 6 (12.5) 5 (26.3) 1 (8.3) 0.28 
Implant infection, n (%) 5 (10.4) 2 (10.5) 3(25.0) 0.37 
Spondylodiscitis, n (%) 2 (5.0) 2 (20.0) - 0.16 
Osteomyelitis, n (%) 1 (2.1) 3 (15.8) 2(16.7) 0.07 
Intraspinal abscess, n (%) - 3 (100.0) -  
Persistent bacteraemia, n (%) 1(2.1) 1 (5.3) 3(25.0) 0.01 




Table 5: Hospital metrics and clinical outcomes 
Parameter n (%)  n (relative %) 
Hospital metrics     
LOS (d), median (IQR) 23 (13-36) 
Readmitted, n (%) 110 (37.8)  
Readmission to ICU, n (%) 16 (5.4) 16 (14.5) 
Time to readmission (d), median (IQR) 52 (15-135) 
LOS readmission (d), median (IQR) 11 (4-21.5) 
 
Clinical outcomes   
Deceased in follow-up time, n (%) 94 (32.3)  
Overall 90-days mortality, n (%) 78 (26.8)  
 HA-SAB, n (%) 40 (51.3) 40 (30.1) 
 HCA-SAB, n (%) 31 (39.7) 31 (28.7) 
 CA-SAB, n (%) 7 (9.0) 7 (14.0)  
   
Time to death (d), median (IQR) 12 (4-26.3)  
Early death (0 - 14 days after SAB) 48 (16.5)  
Intermediate death (14 - 30 days after 
SAB) 
19 (6.5)  
Late death (30 - 90 days after SAB) 12 (4.1)  
   
Sepsis  165 (56.7)  
Uncomplicated SAB 79 (27.1)  
Implant infection 37 (12.7)  
Spondylodiscitis 36 (12.4)  
Infective endocarditis 26 (8.9)  
Osteomyelitis 25 (8.6)  
Persistent bacteraemia 15 (5.2)  
Intraspinal abscess 13 (4.5)  
Haematogeneous spread 12 (4.1)  
   
Acute liver failure 39 (13.4)  
   
Acute renal failure (AKIN)   
No 170 (58.4)  
Stage 1 = Risk 43 (14.8)  
Stage 2 = Injury 35 (12)  
Stage 3 =Failure 40 (13.7)  
   
N of complications per patient   
none 79 (27.1)  
1 129 (44.3)  
2 51 (17.5)  
3 24 (8.2)  





3. Evaluation of SAB parameters 
Assessed SAB characteristics are listed in Table 6. 
44.3% of SAB cases were hospital-acquired, 37.1% healthcare-associated and 18.5% community-
acquired. In 55.0% of patients, S. aureus could be sampled from another site, predominantly from 
concomitant wounds/ ulcera or intraoperative swabs from infected sites (both 16.8%). The median 
time from positive sample to SAB was 0 (sample and blood culture were taken at the same day) with 
an IQR from -7 to 1 day. Minimum and maximum time spans of colonization were -1,054 days before 
to 209 days after SAB. 16.8% of patients already have had a previous episode of SAB in the preceding 
6 months, 69.38% of them were diagnosed with SAB in an external hospital. Time from last to 
present SAB was in average 236.63 days with a median of 38 (IQR 4-209) days. Relapses occurred 
more frequently in patients who already have had prior episodes of SAB (p=0.018). Total incidence 
density rate of relapse was 22/ 68,336 patient-days (pd) or 0.32/ 1,000 patient-days. 
Applying the definitions as specified in the overview (Definitions), the primary source of SAB 
remained unknown in 61.9% of cases. Wound infection (17.5%), central venous line (6.9%) and 
pneumonia (6.1%) were predominant sources. Less common foci were early-onset prosthetic device 
infection (3.8%), peripheral venous line (1.7%), preceding paravertebral infiltration (0.7%), urological 
infection (0.7%), infected haemodialysis shunt (0.3%) and nasopharyngeal focus (0.3%). There was no 
statistically significant association between focus of SAB and death or 90-days survival. 
SAB due to MRSA occurred in 4.5%, mostly in HCA-SAB (46.1%) followed by HA-SAB (38.6%). In 
patients with MRSA-SAB, concomitant colonization of the oropharynx was found in 76.9%, whereas 
patients with MSSA-SAB were colonized in 0.7% only. Overall, 4.1% of patients were colonized with 
MRSA. 
Table 6: SAB characteristics 
Parameter n (%)  n (relative%) 
Mode: Hospital-acquired (HA-SAB) 133 (45.7)  
Mode: Healthcare-associated (HCA-SAB) 108 (37.1)  
Mode: Community-acquired (CA-SAB) 50 (17.2)  
MRSA-SAB 13 (4.5) 13 (100) 
 n (%) in CA-SAB 2 (0.7) 2 (15.38) 
 n (%) in HCA-SAB 6 (2.1) 6 (46.1) 
 n (%) in HA-SAB 5 (1.7) 5 (38.46) 
Nasal MRSA carriage 12 (4.1)  
Nasal MRSA carriage in SAB due to MSSA 2 (0.7)  
Nasal MRSA carriage in SAB due to MRSA 10 (76.9)  
 
Isolation of S. aureus from other location 160 (55.0)  
 
Previous culture of S. aureus: Localization 
Wound/ ulcus 49 (16.8) 49 (30.6) 
Intraoperative swab 49 (16.8) 49 (30.6) 
Upper respiratory tract 29 (10.0) 29 (18.1) 
Indwelling device 17 (5.8) 17 (10.6) 
Urine 6 (2.1) 6 (3.8) 
Lower respiratory tract 6 (2.1) 6 (3.8) 




Previous episodes of SAB in the last 6 months 49 (16.8)  (100) 
SAB diagnosed in external hospital 34 (11.7) 34 (69.38) 
Days from previous to present SAB, median (IQR) 38 (4-209) 
Days from admission to onset of SAB, median (IQR) 2 (1-8) 
Days from culture S. aureus to SAB, median (IQR) 0 (-7-1) 
Patients with a relapse, n (%) 22 (7.6)  
Days to relapse from initial date SAB, median (IQR) 74 (33– 168) 
 
Eradicable focus. n (%) 157 (54.0)  
 
Primary focus of SAB 
Unknown 180 (61.9)  
Wound infection/ abscess/ ulcus 51 (17.5)  
Central venous line 20 (6.9)  
Pneumonia 18 (6.2)  
Prosthetic device infection (early onset) 11 (3.8)  
Peripheral venous line 5 (1.7)  
Paravertebral infiltration 2 (0.7)  
Urological 2 (0.7)  
Hemodialysis shunt 1 (0.3)  
Nose/ throat 1 (0.3)  
 
 
4. Adherence to bundle constituents and assessment of antimicrobial therapy 
Table 7 shows the adherence to bundle constituents and the assessment of antimicrobial therapy; 
Figure 4 synoptically depicts the distribution of important time parameters. 
 
Table 7: Adherence to bundle constituents and assessment of antimicrobial therapy 
Parameter n (%)  n (relative %) 
   
Evaluation of follow-up blood cultures (FUBC) 
FUBC collected, n (%) 178 (61.6)  
Number of FUBC taken of first sampling date,  2 (1-2) 
median (IQR)  
Total number of FUBC, median (IQR) 3 (2-5) 
Total number of FUBC sampling dates, median (IQR) 2 (1-2.8) 
FUBC sterile at first date, n (%) 
 
119 (66.9) 
Intermittently negative FUBC  10 (5.6) 
Days to FUBC from SAB, median (IQR) 5 (3-7) 
Presence of SAB care bundle text on lab report 254 (87.3)  
 
Antibiotic therapy 
Patients with empiric antibiotic therapy, n (%) 272 (93.5)  
Empirical therapy with efficacy against S. aureus, n (%) 262 (90)  
Time from admission to empiric therapy (d), 2 (0-8) 




Number of empiric antibiotics, n (%) 
None 15 (5.2)  
1 170 (58.4)  
2 81 (27.8)  
3 20 (6.9)  
> 3 1 (0.3)  
Missing information 4 (1.4)  
 
Indication of empiric therapy 
Inflammatory constellation, unknown focus  89 (32.7) 
Skin and soft tissue infection  44 (16.2) 
Hospital acquired pneumonia  20 (7.4) 
Community acquired pneumonia  19 (7.0) 
Missing information  17 (6.3) 
Spondylodiscitis  16 (5.9) 
Urinary tract infection  15 (5.5) 
Microbiologically confirmed BSI  13 (4.8) 
Central line associated bloodstream infection  11 (4.0) 
Abdominal focus  9 (3.3) 
Thrombophlebitis  8 (2.9) 
Foreign body infection  8 (2.9) 
Surgical site infection  5 (1.8) 
Multiple foci  5 (1.8) 
Fever in neutropenia  3 (1.1) 
Meningitis  3 (1.1) 
Infective endocarditis  3 (1.1) 
Bone or joint infection  2 (0.7) 
CLABSI  1 (0.3) 
 
Class of empirically administered antibiotics 
β-lactam-/β-lactamase inhibitor formulation 104 (38.2) 
Combination of β-lactam-β-lactamase inhibitor formulation plus MLS 28 (10.2) 
ß-lactam 26 (9.5) 
Cephalosporine 25 (9.1) 
Missing data 23 (8.4) 
Other 22 (8.2) 
MLS 20 (74) 
Quinolones 11 (4.1) 
Combination quinolone plus MLS 4 (1.5) 
Combination Cefotaxime/ Metronidazole 4 (1.5) 
Combination β-lactam-β-lactamase inhibitor formulation plus quinolone 3 (1.1) 
Combination cephalosporine plus MLS 1 (0.4) 
Combination carbapenem plus MLS 1 (0.4) 
 
Empiric use of broad-spectrum antibiotics 
Piperacillin/ Tazobactam, n (%)  85 (31.25) 
Imipenem or Meropenem, n (%)  42 (15.44) 
Vancomycin, n (%)  44 (16.17) 
   
Initiation Flucloxacillin or Cefazolin (FLU/CZO), n (%) 145 (53.3)  
Duration of FLU/CZO treatment (d), mean (IQR) 12 (5-18) 
Switch to another drug from FLU/CZO or  
addition of another drug, n (%) 




Empiric treatment covering MRSA  6 (46.2) 
Targeted treatment of MRSA:   
Vancomycin  3 (23.1) 
Linezolid  3 (23.1) 
Daptomycin  3 (23.1) 
 
Total duration of therapy (d), median (IQR) 15.5 (8.3-25) 
Duration per complication (d), median (IQR) 
Infective endocarditis 27 (11-46) 
Spodylodiscitis 44 (24-54) 
Implanted device infection 23 (15-32) 
Osteomyelitis 24 (17-38) 
Intraspinal abscess 30 (25-45) 
Sepsis 15 (8-25) 
Haematogenous spread 25 (20-31) 
Persistent bacteraemia 14 (9-28) 
Uncomplicated course 11 (6-17) 
 
Duration depending on number of complications (d), median (IQR) 
None 11 (6-17) 
1 14 (7-20) 
2 26 (14-46) 
3 25 (11-34) 
4 28 (23-87) 
 
End of therapy due to death: 64 (23.5)  (100) 
Duration of antibiotic therapy <7 days  - 
Duration of antibiotic therapy 7-16 days  46 (71.9) 
Duration of antibiotic therapy 16– 30 days  12 (18.8) 
Duration of antibiotic therapy > 30 days  3 (4.7) 
 
Duration of therapy not limited by death: 208 (76.4)  (100) 
Duration of antibiotic therapy <7 days  23 (11.1) 
Duration of antibiotic therapy <7-16 days  63 (30.3) 
Duration of antibiotic therapy 16– 30 days  72 (34.6) 
Duration of antibiotic therapy > 30 days  45 (21.6) 
 
Relapse, n (%) 22 (7.6)  
Time to relapse (d), median (IQR) 42 (25-146) 
Total duration of treatment <7 days  1 (4.5) 
Total duration of treatment 7 - 16 days  7 (31.8) 
Total duration of treatment 16 - 30 days  6 (27.2) 
Total duration of treatment >30 days  6 (27.2) 
Not treated  2 (9.1) 
  
Diagnostic procedures performed 
CT-Scan 117 (76.5)   
Chest X-Ray 216 (74.2)   
TTE 187 (64.3)   
TEE 118 (40.5)   
MRT 64 (22.0)   
PET-CT scan 52 (17.9)  
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Specific parameters of antibiotic therapy (see Figure 4) 
TA (d): Empiric therapy → SAB (d), median (IQR) 0 (0-1) 
TB (d): Empiric therapy → FUBC (d), median (IQR) 4 (2-4) 
TC (d): Empiric therapy → Step down to FLU/CZO (d), median (IQR) 3 (1-4) 
TD (d): Initiation FLU/CZO →FUBC (d), median (IQR) 2 (0-5.75) 
TE (d): Onset of SAB → Initiation of FLU/CZO (d), median (IQR) 3 (2-4) 
TF (D): Admission → SAB (d), median (IQR) 2 (1-8) 
TG (D): SAB → FUBC (d), median (IQR) 4 (2-6) 
 
 
Figure 4: Specific parameters of antibiotic therapy 
Empiric therapy was administered mostly simultaneously to drawing the index blood culture (0 days, IQR 0-1). Median time 
from index BC to targeted therapy with Cefazolin or Flucloxacillin was 2 days (IQR 0-5.75), the median time from start of 
empiric to step-down therapy was 3 days (IQR 1-4). Median time from index BC to sampling of the first FUBC was 4 days 
(IQR 2-6). Time from targeted therapy to FUBC was 2 days (IQR 0-5.75). 
 
SAB care bundle summary 
The SAB bundle text summarizing the important cornerstones of management had to be added 
manually and was present on 87.3% of electronic laboratory reports.  
Follow-up blood cultures 
In 61.6% of cases, follow-up blood cultures were taken. The median number of FUBC was 3 (IQR 2-5) 
on a median of 2 sampling dates (IQR 1-2.75). Thus, on each sampling date, a mean of 1.5 FUBC was 
taken. From all sampled follow-up blood cultures 66.85% were sterile at the first sampling time point, 
intermittently negative FUBC occurred in 5.6%. The median time from onset of SAB to collection of 
follow-up blood cultures was 4 days (IQR 2-6 days). As this time frame is too long to assess early 
microbiological success and less than three bottle pairs on each sampling date may be insufficient to 
document true clearance, no statistical calculation was made to assess association between the 
diagnostic and prognostic value of FUBC (survival dependent of time to bloodstream clearance).  
Empiric and targeted therapy 
Empiric antibiotic therapy was administered in 93.47% of cases (272 patients). Median time from 
admission to initiation of empiric therapy was 2 days (IQR 0-8). Leading indications of empiric 
antibiotic therapy were inflammatory constellation with unknown focus (30.6%), skin and soft tissue 
infections (15.1%), hospital acquired pneumonia (6.9%), community acquired pneumonia (6.5%), and 
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spondylodiscitis (5.5%). The median time from initiation of empiric therapy to drawing the index BC 
was 0 (IQR 0-1). In most patients (58.4%), one antibiotic was prescribed, a combination of two drugs 
was given to 27.8%, three in 6.9% and more than three drugs in 0.3%. 90% received a drug with 
proven in-vitro efficacy against the particular S. aureus strain cultivated. Predominantly prescribed 
classes of antimicrobial substances were β-lactam-β-lactamase inhibitor formulations (38.1%), 
combinations of β-lactam-β-lactamase inhibitor formulations with 
Macrolide/ Lincosamide/ Streptogramine class antibiotics (MLS; 10.2%), Flucloxacillin and Cefazoline 
(4.2%) and Cephalosporines (12.8%). Focussing on the empiric use of classes with extremely broad-
spectrum 42 patients (15.44%) received Imipenem or Meropenem and 44 (16.17%) were treated 
with Vancomycin.  
Univariate Cox regression analysis for empirical administration of a β-lactam-/β-lactamase inhibitor 
formulation showed a two-fold increased risk for 90-days-mortality  
(p=0.001, HR 2.28, 95% CI 1.41-3.68, Figure 5). 
 
Figure 5: Kaplan-Meier-curve for empirical ß-lactam/ ß-lactamase inhibitor combination.  
Included cases: MSSA-SAB (n=278) 
 
 
In a multivariate Cox regression model containing the variables age >65 years, sepsis, empirical 
administration of a ß-lactam-/ ß-lactamase inhibitor combination, and targeted treatment with 
Flucloxacillin or Cefazolin, the empirical regimen with a ß-lactam/ ß-lactamase-inhibitor combination 
still showed significance with a HR of 2.14 (p=0.003, 95% CI 1.30-3.53, Table 8). 
 
Table 8: Multivariate Cox regression model (MSSA-SAB, n=278) 
  
Parameter p-value HR 95% CI for HR 
Age >65 years 0.021 1.89 1.09-3.24 
Sepsis <0.001 5.17 2.55-10.47 
Empirical administration of a ß-lactam/ ß-lactamase-
inhibitor combination 
0.003 2.14 1.30-3.53 




145 patients (53.3%) have received a targeted treatment with Flucloxacillin or Cefazolin. In 53 cases 
(36.6%), another drug was added to Flucloxacillin/ Cefazolin treatment or treatment was switched to 
another drug. 123 patients (84.8%) received Flucloxacillin, 22 (15.2%) Cefazolin. 
No 30- and 90-day survival benefit could be seen for a targeted treatment with Flucloxacillin/ 
Cefazolin (n=115) compared to any other antibiotic regimen (n=149) (p90 days=0.41, Figure 6). 
No association was found between one of the substances and acute renal failure (p=0.35). 
There was no association between mode of treatment (ICU vs. non-ICU) and initiation of one of the 
substances (p=0.77). In ICU patients, where SAPS and SOFA scores were available, means between 
groups (treated with Flucloxacillin/ Cefazolin, not treated with Flucloxacillin/ Cefazolin and not 
treated at all) did not differ significantly (p=0.90 for SAPS Score and p=0.18 for SOFA score). 
Proper dosing (n=87) vs. underdosing (n=22) of Flucloxacillin or Cefazolin had no influence on all-
cause 30- and 90-days mortality (p90d=0.32). Time from onset of SAB to initiation of Cefazolin or 
Flucloxacillin did not influence survival significantly, either. Cox regression did not show an impact on 
survival based on timing of targeted therapy. There was no difference in 30- and 90-days mortality 
depending on the substance used (Flucloxacillin vs. Cefazolin) (Table 7).  
 
 
Figure 6: Kaplan-Meier curve for Initiation of Flucloxacillin/ Cefazolin vs. any other treatment 




Table 7: Univariate analyses of the influence of different variables upon survival  
Parameter p-value HR 95% CI for HR Patients included 
90-days survival   
Flucloxacillin vs. Cefazolin 0.41 0.65 (0.23-1.82)  Patients receiving FLU/  
Adequate dosing 0.89 1.06 (0.44-2.55) CZO, n=145 
Time to initiation of FLU/CZO 0.34 0.96 (0.88-1.04)  
Duration of therapy (FLU/CZO) 0.38 0.97 (0.91-1.04) FLU/CZO duration not 
   limited by death (n=116) 
30-days survival   
Flucloxacillin vs. Cefazolin 0.63 0.77 (0.27-2.22) Patients receiving FLU/  
Adequate dosing 0.93 1.04 (0.39-2.71) CZO, n=145 
Time to initiation of FLU/CZO 0.36 0.96 (0.88-1.05)  
Duration of therapy (FLU/CZO) 0.17 0.87 (0.71-1.06) FLU/CZO duration not 
   limited by death (n=116) 
 
 
Duration of therapy 
The median total duration of antibiotic therapy was 15.50 days (IQR 8.25-25); data were available for 
264 patients. 
In the 208 patients where duration of therapy was not limited by death, 86 (41.3%) received a short 
course up to 16 days, 72 (34.6%) a duration of 16 to 30 days, 45 (21.6%) a long course over 30 days 
duration and for 5 (2.4%) data on treatment duration were missing. Median duration of therapy was 
17 days (IQR 11-28) in this group. There was no statistically significant difference between the mean 
durations in ICU- and non-ICU patients (p=0.539). 
In the Cox regression model for total duration of therapy (d), HR for 90-days death was not 
significantly different for longer durations of treatment (p=0.08, HR 0.95, CI 0.90-1.00).  
Total duration of treatment differed between the complication groups, with the longest observed 
duration in spondylodiscitis (44 days, IQR 23.5-53.8), followed by intraspinal abscess (30 days, IQR 
25.0-45.0), infective endocarditis (26 days, IQR 11.25-45.5), haematogenous spread (24.5 days, IQR 
20.00-31.25), osteomyelitis (23.5 days, IQR 16.75-38.00), implant infection (23 days, IQR 15.25-
32.00), sepsis (15 days, IQR 8.3-24.8), persistent bacteraemia (13.5 days, IQR 9.0-27.5) and the 
uncomplicated course (11 days, IQR 6.00-17.00).  
 
Correlation of initial diagnosis and presumptive focus of SAB 
A good correlation between clinical presentation (which led to initiation of the empiric therapy) and 
the primary focus of SAB was present in patients with CAP, early prosthetic device infection, CLABSI, 
thrombophlebitis, SSTI, meningitis after paravertebral infiltration, and haemodialysis shunt infection. 
In cases initially diagnosed as HAP, pneumonia was the focus of bacteraemia in 10% only, central or 
peripheral venous line were the focus in 5% each; in 80% of cases, the primary focus remained 
unknown.  
In patients with fever in neutropenia, CLABSI was the focus in 66.6%. 
Patients presenting with an abdominal problem had a CLABSI as the focus of SAB in 33.3%. In 66%, 
the focus remained elusive. 
The primary focus remained unknown in 66.7% of patients with meningitis and in 29.5% of patients 
with SSTI. Patients who received antibiotics primarily because of the microbiologically confirmed SAB 
had an underlying SSTI in 30.8% and unknown focus in 53.8%. 
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In the group of infection constellation with unknown focus no focus for SAB was found in 69.7%, 
11.2% had an underlying SSTI (wound, abscess or ulcus), 2.20% a prosthetic device infection (early 
onset), pneumonia in 7.90% , urological focus in 1.10%, CLABSI in 6.70% and peripheral venous line-
associated BSI  in 1.10%. 
No primary focus was evident in 81.3% of cases presenting with spondylodiscitis and infectious 
endocarditis. 
 
Removal of catheters 
81 patients had a CVC in place before the onset of SAB. In 20 (24.6%) of them, CVC was the focus of 
SAB according to the definition criteria (Definitions), thus resulting in an incidence density rate of 
3.9/ 1,000 line-days. CVC was changed or removed within 5 days of onset of SAB in 15 patients (75%). 
There was no correlation between the presumptive focus of SAB and catheter change (p=0.31), 
although in the group with CVC removal the central line was believed to be the focus in 33.3% vs. 
11.5% in the group where the central line has not been changed. Haemodialysis shunt infection was 
found in one patient and led to shunt removal. Removal of a pre-existing central venous line 
significantly increased 30- and 90-days survival (p=0.005, Figure 7). 
 
Figure 7: Kaplan-Meier curve for removal of CVC 
 
Adherence to the care bundle 
Supposed the core components of the recommendations for handling SAB are  
• Initiation of Cefazolin or Flucloxacillin in MSSA-SAB (administration for at least 3 days) 
• Initiation of Vancomycin or Daptomycin in MRSA-SAB 
• Sampling of FUBC for diagnostic purposes and calculation of therapy duration 
• Exclusion of an infective endocarditis with a TTE and/ or TEE  
• Administration of 16-30 days of effective antibiotic treatment, 
 




Adherence to the core components of the bundle did not have a significant effect on 90-days-
survival. Survival curves were modelled for all patients (n=291, p=0.25), for cases where duration of 
therapy was not limited by death (n=204, p=0.56), and for cases with MSSA and duration of therapy 
not limited by death (n=200, p=0.66, Figure 8). 
 
Figure 8: Kaplan-Meier curve for adherence to the core components of the SAB bundle 
Included cases (n=200): Duration of therapy not limited by death, MSSA-SAB  
 
 
Influences on relapse rates 
For the analysis of a possible association between duration of therapy and relapse, only treated 
patients in whom duration of therapy was not limited by death were included (n=189). 
Univariate analyses failed to show an effect of a longer treatment courses, initiation of Cefazolin or 
Flucloxacillin, and bundle adherence upon recurrence or relapse. The only variable associated with 
an increased risk of relapse was a previous episode of SAB in the patient`s history, although the 
result failed to reach statistical significance (p=0.064, HR 2.27, 95% CI 0.95-5.42) (Table 9). 
 
Table 9: Impact of different variables upon relapse, univariate analyses 
Parameter  p-value HR 95% CI for HR Patients included 
Relapse in available follow-up time  
Initiation of CZO or FLU 0.56 1.23 (0.61-2.47) all 
Bundle adherence 0.59 1.31 (0.48-3.28)  
Previous SAB episode 0.064 2.27 (0.95-5.42)  
   
Duration of therapy 0.22 1.01 (0.99-1.02) Duration of therapy not  





5. Resistance patterns and typing of strains 
Resistance patterns and spa types 
Table 10 gives an overview on cumulative resistance patterns. From the 291 primary isolates tested, 
35,4% were resistant to Penicillin only and 32.6% were pan-susceptible, thus comprising the majority 
of strains. 7.9% showed resistance against Penicillin plus quinolones, another 7.9% had resistance to 
Penicillin plus an MLSBi/MSB phenotype with resistance to Roxithromycin. 2.4% were MRSA strains 
with constitutive MLSB resistance and quinolone resistance. 2.1% were resistant to quinolones only, 
1.7% showed MLSBi/MSB phenotype only 93.1% of strains with MLSBi/MSB phenotype in microbroth 
dilution had an inducible MLSB resistance phenotype in the D-Test, 6.89% had an MSB phenotype. 
Two strains were resistant to Daptomycin (confirmed with E-Test). 
From 13 MRSA strains, one was PVL-positive. MSSA were not routinely tested for presence of PVL. 
Investigating the overall distribution of phenotypes in patients during their stay or during multiple 
stays, 26.5% had more than one resistance phenotype in S. aureus strains cultivated (blood cultures 
and other sites). In 30.9%, S. aureus was cultured only once. 
Overall, 141 different spa types were determined. The spa type per isolate ratio was 0.48 indicating a 
highly diverse population of infecting S.aureus strains. The top 20 ranking spa types (Table 11) 
included 52.58% of all isolates. Predominant spa types in all primary isolates were t008 (7.2%), t091 
(6.5%), t608 (5.9%), t002 and t012 (both 4.5%), and t015 (2.4%).  
Table 10: Cumulative resistance patterns 
Cumulative resistance phenotype n (%) n (relative %) 
BEN 103 (35.39) 
Pan-susceptible 97 (33.3) 
BEN, CIP, MOX, LEV 23 (7.9) 
BEN, ROX 23 (7.9) 
BEN, OXA, ROX, CLI, CIP, MOX, LEV 7 (2.4) 
CIP, MOX, LEV 6 (2.1) 
ROX 3 (1) 
BEN, DOX 3 (1) 
BEN, OXA 3 (1) 
ROX, CLI 3 (1) 
BEN, CIP 2 (0.7) 
BEN, OXA, CIP, MOX, LEV 2 (0.7) 
BEN, ROX, CLI, CIP, MOX, LEV 2 (0.7) 
BEN, TRS 2 (0.7) 
ROX, AMI, GEN 2 (0.7) 
CIP, MOX, LEV, RIF 1 (0.3) 
DAP 1 (0.3) 
BEN, DAP 1 (0.3) 
BEN, FOS 1 (0.3) 
BEN, OXA, CIP, MOX, LEV, AMI 1 (0.3) 
BEN, RIF 1 (0.3) 
BEN, ROX, CIP, DOX, AMI 1 (0.3) 
BEN, ROX, CLI 1 (0.3) 
BEN, ROX, CLI, AMI, GEN 1 (0.3) 
ROX, CLI, AMI, GEN 1 (0.3) 
  
MLSB induced 27 (9.27) (93.1) 
MSB phenotype 2 (0.68) (6.89) 
MRSA-SAB 13 (4.4)  
MRSA, PVL-positive 1 (0.3) (7.69) 
  
More than one phenotype present in patients 77 (26.5) 
One-time S. aureus isolation 90 (30.9) 
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Table 11: Spa type distribution overall 
Rank spa type n %  Cumulative % 
1 t008 21 7.22 7.22 
2 t091 19 6.53 13.75 
3 t608 17 5.84 19.59 
4 t084 15 5.15 24.74 
5 t002 13 4.47 29.21 
6 t012 13 4.47 33.68 
7 t015 7 2.41 36.08 
8 t021 5 1.72 37.80 
9 t065 5 1.72 39.52 
10 t346 5 1.72 41.24 
11 t571 5 1.72 42.96 
12 t056 4 1.37 44.33 
13 t026 3 1.03 45.36 
14 t032 (MRSA) 3 1.03 46.39 
15 t085 3 1.03 47.42 
16 t1081 3 1.03 48.45 
17 t1451 3 1.03 49.48 
18 t230 3 1.03 50.52 
19 t307 3 1.03 51.55 
20 t647 3 1.03 52.58 
Other - 138 47.42 100.00 
 
In MRSA, t032 was predominant (3 isolates, 23.08% of MRSA). Table 12 shows the spa types 
distribution between CA- , HCA- and and HA-MRSA. 
 
Table 12: Spa type distribution in HA- and CA-MRSA 
MRSA 
CA 
n % MRSA 
HCA 
n % MRSA HA n % 
Overall 2 100 Overall 6 100 Overall 5 100 
t1610 1 50.0 t032 2 33.3 t002/t023 1 20.0 
t790 1 50.0 t022 1 16.7 t032 1 20.0 
   t379 1 16.7 t062 1 20.0 
   t564 1 16.7 t608 1 20.0 





The distribution of the most frequent spa types (ranks 1-20) between the modes of acquisition is 
depicted in Figure 9.  
It can already be seen that there is a trend towards a different distribution between CA-SAB and 
HCA- and HA-SAB. Predominant spa types in HA-SAB were t008 (8.5%), t608 (8.5%), t084 (7.8%), t091 
(7%),and t012 (5.4%) with the rest of each spa type accounting for less than 3%. In HCA-SAB, the 
distribution was t008 (7.4%), t091 (6.5%), t002, t012 and t608 (4.6% each) for the first five ranks. In 
CA-SAB, dominating spa types were t002 (10%), t084 (6%), t008, t021 and t091 (4% each). 
 
 
Figure 9: Distribution of spa types depending on mode of acquisition, ranks 1-20 
 
Looking at spa types in cases with no, one, two, three or four complications present, t008 was 
leading in all complication groups with being on third rank in the group with two complications only 
but playing no role in patients with uncomplicated SAB (Figure 10). However, after Bonferroni 
correction, spa type t008 lacked statistical significance in predicting a complicated course.  
Spa type t608 has shown a moderately strong association with an uncomplicated course (p=0.001, 
Cramer`s V 0.28). 
Taking into account the type of underlying complication, t008 was the predominant spa type in all 
complication groups excluding haematogenous spread, where t304 was dominating (Figure 11). 
However, there was no statistically significant correlation between the top 6 ranking spa types and 




















Figure 10: Spa type distribution depending on number of complications (ranks 1-5) 
 




Spa CCs after Based Upon Repeat Patterns (BURP) grouping 
To predict the clonal relatedness of S. aureus isolates, a grouping algorithm called BURP (“based 
upon repeat patterns”) was used to cluster closely related spa types. This algorithm has been 
described to be highly concordant with multilocus sequence typing (96.5% concordance) and pulsed-
field gel electrophoresis (94.9%) in inferring clonal relatedness (Mellmann et al. 2008).  
BURP grouping using the described default parameters resulted in 15 spa CCs, 15 singletons (#), and 
13 excluded spa types (spa types t026, t322, t362, t605, t991, t1050, t1509, and t3812) (Table 13, 
Figure 12). Ranks 1-10 contained 81.8% of the 291 primary isolates. In 15 spa types, no alignment 
was found in the database. Predominant spa CC were spa CC 084/346 (19.6% of primary isolates), 
spa CC 790 (18.2%), spa CC 015 (12.7%), spa CC 012 (9.3%), spa CC 002 and spa CC 008/024 (5.2% 
each).  
In Figure 12, the size of each circles indicates the number of isolates that were assigned to that 
spa type. Clusters of linked isolates correspond to spa CCs. The spa type with the highest founder 
score is defined as the founder of the cluster and is coloured dark blue. Yellow circles indicate 
subfounders, which are the spa types with the second highest founder score. If two spa types have 
an equally high founder score, both are coloured dark blue. Note that the spacing between linked 
and unlinked spa types and spa CCs does not provide information about the genetic distance 
between them. Spa CCs without founder and singletons are included in the figure at the bottom. 
Predominant spa CCs were spa CC 084/346 (19.6%), spa CC 790 (18.2%), spa CC 015 (12.7%), 
spa CC 012 (9.3%), spa CC 002 and 008/024 (5.2% each) and spa CC 065/330 (3.8%), showing 
concordance to a Norwegian study investigating 353 S. aureus bloodstream isolates in which 
spa CC 084, spa CC 065 and spa CC 002 were amongst the most frequent spa CCs as well (Aamot, 
Blomfeldt, and Eskesen 2012). The relation between spa type and spa CC and onset of SAB, 30- and 
90-days all-cause mortality and complications are shown in Table 14 and Table 15. 
There was no statistically significant correlation between the top 7 ranking spa CC and 30-days/ 90-
days all-cause mortality (p30d=0.59 and p90d=0.61). Although Pearson Chi-Square showed a p=0.045 
for the test on independence of spa CC and onset of SAB (CA-, HCA- or HA-SAB), there could be not 
found a statistically significant effect in post-hoc analysis after Bonferroni correction of the p-value. 
There seems to be a tendency towards association of spa CC 008/024 and nosocomial onset, but 
sample size was probably too small to demonstrate statistical significance.  
No associations were found between the top 7 ranking spa CC as well as the top 6 ranking spa types 
and the presence of each type of complication. Spa CC 008/024 and spa CC 002 were strongly 




Table 13: BURP grouping results 
BURP-
Cluster 
Spa CC Spa types Frequency (%) Cumulative % 
2 084/346 t084, t085, t091, t252, t289, t346, t360, 
t385, t491, t499, t760, t1716, t1875, 
t2616, t2932, t4004, t5804, t15649 
57 (19.6) 19.6 
3 790 t005, t022, t032, t223, t309, t379, t608, 
t651, t790, t885, t891, t4920, t7418, 
t14803 
53 (18.2) 37.8 
1 015 t015, t050, t073, t230, t302, t331, t487, 
t571, t620, t728, t950, t1081, t1451, 
t1823, t3307, t5529, t6406, t12321 
37 (12.7) 50.5 
5 012 t012, t018, t021, t076, t122, t338, t342, 
t2387, t3732 
27 (9.3) 59.8 
8 002 t002, t214, t548 15 (5.2) 65.0 
4 008/024 t008, t024, t068, t190, t207, t211, t304, 
t334, t701, t711, t1171, t1610, t2427, 
t8151 
15 (5.2) 70.2 
6 056 t056, t514, t1541, t2292, t3760 8 (2.7) 72.9 
9 065/330 t040, t065, t330 11 (3.8) 76.7 
7 148 t148, t1346, t3682, t6723 6 (2.1) 78.8 
10 078 t078, t258, t660 3 (1) 81.8 
15 no founder t764, t1255 3 (1) 82.8 
singleton #10 t647 3 (1) 79.8 
singleton #8 t307 3 (1) 80.8 
singleton #5 t209 2 (0.7) 83.5 
singleton #6 t209 2 (0.7) 84.2 
11 no founder t564, t5923 2 (0.7) 84.9 
12 no founder t1491, t1931 2 (0.7) 85.6 
13 no founder t127, t11278 2 (0.7) 86.3 
singleton #1 t062 1 (0.3) 86.6 
singleton #11 t871 1 (0.3) 86.9 
singleton #12 t884 1 (0.3) 87.2 
singleton #13 t1166 1 (0.3) 87.5 
singleton #14 t11004 1 (0.3) 87.8 
singleton #15 t17080 1 (0.3) 88.1 
singleton #2 t136 1 (0.3) 88.4 
singleton #3 t156 1 (0.3) 88.7 
singleton #4 t189 1 (0.3) 89.0 
singleton #7 t246 1 (0.3) 89.3 
singleton #9 t370 1 (0.3) 89.6 
8/3 002/790 
 
1 (0.3) 89.9 
14 no founder t364, t493 1 (0.3) 90.2 
no alignment 
 
15 (5.2) 95.5 
excluded 
  
12 (4.1) 100.0 





Figure 12: Spa clonal complexes after Based Upon Repeat Patterns (BURP) analysis 
© Dr. Franziska Layer  
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Table 14: Spa type and spa CC in relation to onset of SAB and 30-/ 90-days all-cause mortality 
Metric No. (%) of isolates CA-SAB HCA-SAB HA-SAB 30d mortality 90d mortality 
spa type 
    
  
t008 21 (7.2) 2 (4.0) 8 (7.4) 11 (8.2) 7 (2.4) 8 (2.7) 
t091 19 (6.5) 2 (4.0) 7 (6.4) 10 (7.5) 2 (0.8) 3 (1.0) 
t608 17 (5.8) 1 (2.0) 5 (4.6) 11 (8.2) 3 (1.0) 3 (1.0) 
t084 15 (5.2) 3 (6.0) 2 (1.8) 10 (7.5) 6 (2.0) 6 (2.0) 
t002 13 (4.5) 5 (10.0) 5 (4.6) 3 (2.2) 2 (0.6) 2 (0.6) 
t012 13 (4.5) 1 (2.0) 5 (4.6) 7 (5.2) 1 (0.3) 1 (0.3) 
Other spa types 193 (66.3) 36 (72.0) 76 (70.3) 81 (60.9) 45 (15.5) 55 (18.9)  
Total 291 50  108  133  66 (22.6) 78 (26.8) 
       
CC 
    
  
spa CC 084/346 57 (19.6) 6 (12.0) 20 (18.5) 31 (23.3) 10 (3.4) 14 (4.8) 
spa CC 790 53 (18.2) 4 (8.0) 20 (18.5) 29 (21.8) 13 (4.5) 16 (5.5) 
spa CC 015 37 (12.7) 11 (22.0) 11 (10.2) 15 (11.3) 8 (2.7) 11 (3.7) 
spa CC 012 27 (9.3) 3 (6.0) 10 (9.3) 14 (10.5) 8 (2.7) 8 (2.7) 
spa CC 002 15 (5.2) 5 (10.0) 7 (6.5) 3 (2.3) 2 (0.7) 2 (0.7) 
spa CC 008/024 15 (5.2) 3 (6.0) 10 (9.2) 2 (2.3) 1 (0.3) 1 (0.3) 
spa CC 065/330 11 (3.8) 2 (4.0) 4 (3.7) 4 (3.0) 3 (1.0) 3 (1.0) 
Other spa CC 76 (26.1) 16 (32.0) 26 (24.1) 35 (26.3) 21 (7.2) 23 (7.9) 
Total 291 50  108  133  66 (22.6) 78 (26.8) 
 
Table 15: Spa type and spa CC in relation to complication of SAB 























       
t008 21 (7.2) 16 (9.7) 2 (7.7) 4 (11.1) 3 (23.0) 5 (13.5) 4 (16.0) 0 2 (13.3) 
t091 19 (6.5) 10 (6.0) 2 (7.7) 2 (5.5) 2 (15.4) 2 (5.4) 5 (20.0) 0 1 (6.7) 
t608 17 (5.8) 5 (3.0) 0  0 0 0 0 1 (7.1) 1 (6.7) 
t084 15 (5.2) 8 (4.8) 2 (7.7) 0 0 1 (2.7) 0 0 0 
t002 13 (4.5) 8 (4.8) 1 (3.8) 1 (2.7) 0 0 1 (4.0) 1 (7.1) 1 (6.7) 
t012 13 (4.5) 3 (1.8) 0 2 (5.5) 0 3 (8.1) 1 (4.0) 0 1 (6.7) 
Other  193 (66.3) 115 (69.7) 19 (73.0) 27 (75.0) 8 (61.5) 26 (70.2) 14 (56.0) 12 (85.7) 9 (60.0) 
Total 291 165  26  36  13  37  25 12 15  




       
084/346 57 (19.6)  7 (21.2) 5 (15.1) 4 (12.1) 8 (21.6) 7 (21.2) 0 2 (13.3) 
790 53 (18.2)  3 (12.5) 0 4 (16.6) 8 (21.6) 5 (20.8) 0 3 (20.0) 
015 37 (12.7)  3 (15.7) 6 (31.6) 0 3 (8.1) 3 (15.7) 1 (8.3) 3 (20.0) 
012 27 (9.3)  3 (18.8) 5 (31.1) 0 4 (10.8) 3 (18.8) 0 1 (6.7) 
002 15 (5.2)  1 (12.5) 0 0 1 (2.7) 2 (25.0) 3 (25.0) 1 (6.7) 
008/024 15 (5.2)  2 (15.3) 3 (23.0) 0 3 (8.1) 1 (7.6) 3 (25.0) 1 (6.7) 
065/330 11 (3.8)  0 1 (25.0) 0 1 (2.7) 0 0 2 (13.3) 
Other  76 (26.1)  7 (11.1) 16 (29.6) 5 (9.2) 9 (24.3) 11 (20.3) 5 (41.7) 2 (3.3) 
Total 291  26  36  13 37  25 12 15  
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Investigation of follow-up isolates 
Table 16 gives an overview over phenotypic resistance patterns and spa types of first and consecutive 
follow-up isolates of S. aureus. 
A different spa type of first and follow-up isolate was found in three patients. In two of them, 
infecting strains occurred simultaneously during the same SAB episode, in the third patient the 
switch occurred during first episode and a relapse four months later.  Some strains exhibited a 
variable Penicillin resistance determined with broth microdilution, which supports EUCAST 
recommendations for zone-edge reading in agar diffusion testing to detect Penicillin resistance. In 
one patient, the first isolate showed inducible MLSb resistance, but the follow-up isolate (relapse six 
months later) was fully susceptible, although the same spa type. Here, an in vitro testing artefact can 
be assumed.  In another patient, two strains from the same blood culture sampling set exhibited 
heterogeneous resistance: Penicillin resistance in one strain, PEN, ROX, CLI, AMK, GEN resistance in 
the other isolate. Besides these two cases, no major differences in phenotypic resistance were 
present in the remaining cases, indicating a close relation of the infecting strains. Interestingly, many 
of those patients were infected and/ or colonized with phenotypically different strains 
simultaneously. However, strains from samples other than blood were not collected prospectively 
and thus were not available for typing. 
 
Table 16: Investigation of follow-up isolates 
Patient ID Resistance phenotype MecA Spa type Sample date of BC 
II-47-AM64 BEN - t015 02.03.2018 
II-48-AM64F BEN - t015 08.03.2018 
I-24-AM70 BEN, ROX - t002 26.06.2017 
I-26-AM70F BEN, ROX - t002 02.07.2017 
III-66-AR45 susceptible - t3307 04.06.2018 
III-70-AR45F susceptible - t3307 08.06.2018 
II-5-BA56 BEN - t491 21.12.2017 
II-6-BA56F BEN - t491 23.12.2017 
II-34-BM41 BEN, CIP, MOX, LEV - t008 12.02.2018 
II-39-BM41 BEN, CIP, MOX, LEV - t008 20.02.2018 
II-49-BM84 BEN, CIP, MOX, LEV - t608 05.03.2018 
III-76-BM84R1 BEN, CIP, MOX, LEV - t608 14.06.2018 
IV-57-BM84R2 BEN, CIP, MOX, LEV - t608 16.11.2018 
IV-58-BM84R2F BEN, CIP, MOX, LEV - t608 17.11.2018 
IV-29-BR49 susceptible - t1931 22.08.2018 
IV-30-BR49F susceptible - t1931 25.08.2018 
IV-14-BW57 BEN - t19235 26.07.2018 
IV-15-BW57F BEN - t19235 01.08.2018 
I-69-CB66 BEN, ROX - t1171 29.04.2018 
III-20-CB66R susceptible - t1171 24.10.2018 
I-65-FD79 CIP, MOX, LEV - t008 06.11.2017 
V-79-FD79R CIP, MOX, LEV - t008 10.06.2019 
II-42-FS78 susceptible - t091 26.02.2018 
II-56-FS78F susceptible - t091 28.02.2018 
IV-3-GI47 ROX - t571 14.07.2018 
IV-6-GI47F ROX - t571 19.07.2018 
III-7-GJ35 susceptible - t12321 14.04.2018 
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III-8-GJ35F BEN - t12321 16.04.2018 
III-14-GJ35F2 not tested - t12321 17.04.2018 
II-59-GJ51 susceptible - t17080 09.03.2018 
II-61-GJ51F BEN, ROX - t065 10.03.2018 
V-60-GS45 BEN, CIP, MOX, LEV - t608 15.05.2019 
V-65-GS45F BEN, CIP, MOX, LEV - t608 18.05.2019 
V-19-HC78 BEN, CIP, MOX, LEV - t608 07.02.2019 
V-20-HC78F not tested - t608 09.02.2019 
V-72-HC78F2 BEN, CIP, MOX, LEV - t608 26.05.2019 
I-74-HG50 susceptible - t026 20.11.2017 
I-77-HG50F susceptible - t026 24.11.2017 
I-78-HG50F2 susceptible - t026 25.11.2017 
V-26-HJ83 BEN - t19234 06.04.2019 
V-45-HJ83F BEN - t19234 08.04.2019 
I-71-KE45 BEN, OXA, ROX, CLI, CIP, MOX, 
LEV 
+ t032 14.11.2017 
I-75-KE45F BEN, OXA, ROX, CLI, CIP, MOX, 
LEV 
+ t032 21.11.2017 
III-33-KF93 BEN, OXA + t1610 14.05.2018 
III-40-KF93F BEN, OXA + t1610 17.05.2018 
IV-78-KH42 BEN, CIP, MOX, LEV - t608 09.12.2018 
V-22-KH42R BEN, CIP, MOX, LEV - t608 08.02.2019 
  susceptible   not typed 08.02.2020 
V-28-KK36 BEN - t487 04.04.2019 
V-39-KK36F susceptible - t487 15.04.2019 
V-43-KK36F2 susceptible - t487 11.04.2019 
III-13-KK40 susceptible - t084 17.04.2018 
III-15-KK40F susceptible - t084 19.04.2018 
II-67-KM38 BEN, OXA, ROX, CLI, CIP, MOX, 
LEV 
+ t564 25.03.2018 
II-73-KM38F BEN, OXA, ROX, CLI, CIP, MOX, 
LEV 
+ t564 27.03.2018 
IV-27-KN40 BEN, ROX - t012 18.09.2018 
IV-42-KN40F BEN, ROX - t012 25.08.2018 
II-77-LH35 susceptible - t084 09.04.2018 
III-2-LH35F susceptible - t084 10.04.2018 
II-68-LJ43 BEN - t4004 31.03.2018 
III-62-LJ43R BEN - t4004 04.06.2018 
IV-18-LJ51 BEN, DOX - t346 10.08.2018 
IV-19-LJ51F BEN, DOX - t346 07.08.2018 
III-26-LJ58 BEN - t1081 06.05.2018 
III-31-LJ58F BEN - t1081 11.05.2018 
II-43-LL08 BEN - t1451 27.02.2018 
II-44-LL08F BEN - t1451 01.03.2018 
I-79-LM36 BEN, ROX, CLI, AMK, GEN - t148 24.11.2017 
II-2-LM36F BEN - t148 24.11.2017 
III-5-LM62 susceptible - t19241 07.04.2018 
III-12-LM62F susceptible - t19241 18.04.2018 
III-34-LT42 susceptible - t008 16.05.2018 
III-38-LT42F susceptible - t008 16.05.2018 
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III-44-LT42F2 susceptible - t008 16.05.2018 
III-37-ME35 BEN, ROX - t012 18.05.2018 
III-54-ME35F BEN, ROX - t012 20.05.2018 
III-55-ME35F2 BEN, ROX - t012 22.05.2018 
IV-04-MHe35 susceptible - t076 16.07.2018 
IV-05-MHe35F susceptible - t076 18.07.2018 
IV-08-MHe35F2 susceptible - t076 20.07.2018 
II-38-MM54 BEN - t647 20.02.2018 
II-40-MM54F BEN - t647 23.02.2018 
IV-49-MR53 BEN - t487 12.11.2018 
IV-55-MR53F BEN - t487 16.11.2018 
IV-56-MR53F2 BEN - t487 17.11.2018 
IV-71-MR53F3 susceptible - t487 08.12.2018 
V-07-MR53F4 susceptible - t487 03.01.2019 
V-10-MR53F5 BEN - t487 25.12.2018 
V-16-NH49 BEN - t647 30.01.2019 
V-17-NH49F BEN - t647 06.02.2019 
V-18-NH49F2 BEN - t647 07.02.2019 
V-77-NH49R BEN, ROX - t065 12.06.2019 
     
II-8-NR40 DAP - t008 22.12.2017 
II-9-NR40F ROX - t008 26.12.2017 
I-51-PE40 susceptible - t073 17.10.2017 
I-54-PE40F BEN - t073 19.10.2017 
II-16-PJ67 BEN, OXA, CIP, MOX, LEV + t032 10.01.2018 
II-35-PJ67F BEN, OXA, CIP, MOX, LEV + t032 12.02.2018 
II-32-PR40 BEN - t252 09.02.2018 
II-33-PR40F not tested - t252 11.02.2018 
III-41-RA35 BEN - t499 17.05.2018 
III-49-RA35F BEN - t499 20.05.2018 
III-50-RA35F2 BEN - t499 23.05.2018 
III-51-RA35F3 BEN - t499 28.05.2018 
III-64-RA35F4 BEN - t499 04.06.2018 
III-68-RA35F5 BEN - t499 08.06.2018 
III-69-RA35F6 BEN - t499 08.06.2018 
III-73-RA35F7 BEN - t499 23.06.2018 
III-35-RH40 BEN - t3812 16.05.2018 
III-45-RH40F BEN - t3812 16.05.2018 
II-80-RT69 DOX - t084 10.04.2018 
III-1-RT69F PEN, DOX - t084 13.04.2018 
I-62-RU41 BEN, OXA + t991 28.10.2017 
I-66-RU41F BEN, OXA + t991 06.11.2017 
I-48-SA91 susceptible - t19149 13.10.2017 
I-55-SA91F susceptible - t19149 17.10.2017 
III-27-SG28 BEN, ROX - t012 06.05.2018 
III-53-SG28F BEN, ROX - t012 22.05.2018 
II-54-SH47 susceptible - t084 05.03.2018 
II-55-SH47F BEN - t084 07.03.2018 
II-57-SH47F2 BEN - t084 11.03.2018 
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III-09-SH47F3 susceptible - t084 16.04.2018 
IV-10-SK39 BEN, CIP, MOX, LEV - t608 24.07.2018 
IV-11-SK39F BEN, CIP, MOX, LEV - t608 26.07.2018 
III-21-SL03 susceptible - t091 24.04.2018 
III-22-SL03F susceptible - t091 01.05.2018 
II-24-TD56 BEN - t19176 27.01.2018 
II-58-TD56F BEN - t19176 10.03.2018 
II-64-TD56F2 BEN - t19176 17.03.2018 
IV-51-UG39 BEN - t605 07.11.2018 
IV-73-UG39F BEN - t605 03.12.2018 
V-47-WD74 ROX, CLI - t015 04.05.2019 
V-48-WD74F not tested - t015 05.05.2019 
V-49-WD74F2 not tested - t015 08.05.2019 
  ROX, CLI   not typed 26.07.2019 
II-14-WJ37 BEN - t304 29.12.2017 
II-22-WJ37F BEN - t304 29.12.2017 
IV-9-WJ37R BEN, RIF - t304 29.07.2018 
V-63-WJ41 PEN - t021 18.05.2019 
V-66-WJ41F not tested - t021 19.05.2019 
V-27-WM98 BEN - t012 31.03.2019 
V-33-WM98F BEN - t012 05.04.2019 
V-44-WM98F2 BEN - t012 09.04.2019 
III-71-ZE37 susceptible - t091 17.06.2018 
III-72-ZE37F susceptible - t002 20.06.2018 
 
Detection of nosocomial transmission: cgMLST Analysis 
To detect possible patient-to-patient cross-transmission which ultimately led to invasive infection, 
isolates from hospital-acquired SAB were checked for similarity in spa type and preferably, but not 
exclusively for the same phenotypic resistance pattern. If their isolation from blood cultures lay not 
more than three months apart, strains were included in the cgMLST analysis. The results of the finally 
included 43 isolates are shown in Table 17 and Figure 13. In the Minimum Spanning Tree, each 
coloured node represents one isolate. The length of the connecting lines (branches) between the 
nodes represents the allelic distance between the isolates based on the number of divergent loci in 
cgMLST. Core Genome MLST Cluster types (CT) contain isolates with their allelic difference being less 
or equal than the CT threshold alleles (in our case 10) distant to an already established CT founder. 
CT founders were assigned by the cgMLST.org nomenclature server during the sample submission 
process. CT thresholds are species-specific and were defined in the Task Template. In our data, 
isolates assigned to the three Cluster Types (1-3) differ in one to two of the 1489 investigated loci 
from each other, therefore indicating a close clonal relatedness and a common origin. 
Resistance genotype and phenotype showed an overall good concordance with the exception of 
minor discrepancies between encoded and phenotypically determined resistances.  
Three distinct clusters could be determined. Cluster 1 consists of two isolates of spa type t012 with 
induced MLSB resistance. The patients did not have any spatial overlap besides visiting the radiology 
department, but both cases of SAB occurred within two weeks. Both cases developed SAB on day 4 
after admission. The short timespan from admission to invasive infection may indicate that both 
patients were colonized prior to their admission and transmission took place in community.  
Both patients live nearby, just 1,6 km apart from each other. Probably those cases are HCA- or CA-
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SAB cases, in fact, but were diagnosed >72h after admission with a delay in blood culture sampling. 
One patient died on day 17 after onset of SAB from septic shock, the focus remained unknown. The 
second patient developed a thrombophlebitis with concomitant SAB and was in the course diagnosed 
with spondylodiscitis.  
In Cluster 2 and Cluster 3 (both spa type t608), patients shared the same ward within 3 months.  
One putative transmission occurred on an ICU ward. Both SAB episodes were 38 days apart. The 
patients developed SAB 75 days and 28 days after admission, respectively. The first patient 
presented with uncomplicated SAB initially but suffered relapses three and seven months after the 
initial episode, respectively, with identical strains according to phenotype and spa typing. During the 
relapses, septic shock and acute renal failure occurred. The second patient developed SAB with 
septic shock 28 days after admission and died three days later. Pneumonia was diagnosed to be the 
presumptive focus. 
The second transmission occurred on a normal ward. SAB episodes were 80 days apart. Patients 
developed SAB 6 days and 52 days after admission, respectively. The first patient developed pleural 
effusions with growth of S. aureus and S. parasanguinis ten days after onset of SAB and suffered a 
relapse 61 days later with accompanying rupture of the thoracic aorta. The second patient was a 
patient with a history of liver transplantation and Graft-versus-host-disease and suffered a relapse 
108 days later presenting with a CA-BSI originating from of the dialysis catheter. 
 
Figure 13: Minimum Spanning Tree of 43 Selected Isolates 




Table 17: Cg-MLST analysis of 43 selected isolates 
Spa Type Sampling Date Isolate ID Shared AMR phenotype AMR genotype cgMLST Cluster 
t008 06.11.2017 I-65-FD79 CIP, MOX, LEV CIP, MOX 21410 none 
t008 25.11.2017 I-80-ZE29 BEN BEN 21413 none 
t008 22.12.2017 II-08-NR40 DAP susceptible 21414 none 
t008 09.01.2018 II-18-BS56 BEN BEN 21415 none 
t008 06.02.2018 II-30-LG56 susceptible susceptible 21416 none 
t008 18.08.2018 IV-21-RFP50 susceptible BEN 21436 none 
t008 23.08.2018 IV-26-HH36 CIP, MOX, LEV CIP, MOX 21437 none 
t012 06.05.2018 III-27-SG28 RAD Amb BEN, ROX BEN, ERY 21425 Cluster 1 
t012 18.05.2018 III-37-ME35 RAD Amb BEN, ROX BEN, ERY 21425 Cluster 1 
t012 29.05.2018 III-48-HP56 BEN BEN, GEN 21429 none 
t012 25.08.2018 IV-27-KN40 BEN, ROX BEN, ERY 21438 none 
t012 18.09.2018 IV-41-LJ45 BEN BEN 21439 none 
t012 31.03.2019 V-33-WM98 BEN BEN 21450 none 
t012 06.05.2019 V-56-SR51 susceptible susceptible 21452 none 
t056 06.11.2017 I-67-SP45 susceptible susceptible 21411 none 
t056 21.11.2017 I-73-PS66 susceptible susceptible 21412 none 
t084 10.04.2018 II-80-RT69 BEN, DOX BEN, TET 21421 none 
t084 18.04.2018 III-13-KKP40 susceptible susceptible 21423 none 
t084 06.11.2018 IV-47-SH55 susceptible BEN 21440 none 
t084 18.12.2018 V-01-LL51 BEN BEN 21448 none 
t084 07.02.2019 V-23-ZO55 BEN BEN 21449 none 
t091 26.02.2018 II-42-FS78 susceptible susceptible 21417 none 
t091 12.03.2018 II-60-WJ27 susceptible RIF i 21419 none 
t091 15.03.2018 II-63-SR39 BEN BEN 21420 none 
t091 11.05.2018 III-29-EL51 BEN BEN 21426 none 
t091 19.05.2018 III-57-HMH69 susceptible susceptible 21432 none 
t091 17.06.2018 III-71-ZE37 BEN susceptible 21434 none 
t091 09.07.2018 III-78-RG30 BEN BEN 21435 none 
t1081 08.04.2018 III-03-SB55 BEN BEN 21422 none 
t1081 06.05.2018 III-26-LJ58 BEN BEN, CXI 21424 none 
t307 19.11.2018 IV-59-DW41 BEN, CIP, MOX, 
LEV 
BEN, CIP, MOX, 
CXI 
21442 none 
t307 30.11.2018 IV-64-JM30 BEN, ROX, CLI, CIP, 
MOX, LEV 
BEN, CIP, MOX 21444 none 
t338 17.05.2018 III-42-HDR18 BEN, ROX BEN, ERY 21427 none 
t338 19.05.2018 III-46-RA72 BEN, ROX BEN, ERY 21428 none 
t608 05.03.2018 II-49-BM84 IOI-C BEN, CIP, MOX, 
LEV 
BEN, CIP, MOX 21418 Cluster 2 
t608 12.04.2018 II-76-KH32 IOI-C BEN, CIP, MOX, 
LEV 
BEN, CIP, MOX 21418 Cluster 2 
t608 06.11.2018 IV-50-SD70 BEN, CIP, MOX, 
LEV 
BEN, CIP, MOX 21441 none 
t608 21.11.2018 IV-60-SR43 BEN BEN 21443 none 
t608 04.12.2018 IV-72-DI39 susceptible susceptible 21445 none 
t608 09.12.2018 IV-78-KH42 G3-2 BEN, CIP, MOX, 
LEV 
BEN, CIP, MOX, 
CXI 
21446 Cluster 3 
t608 11.12.2018 IV-80-JM56 BEN, OXA BEN, OXA, CIP, 
MOX, CXI 
21447 none 
t608 07.02.2019 V-19-HC78 G3-2 BEN, CIP, MOX, 
LEV 
BEN, CIP, MOX 21446 Cluster 3 
t608 29.03.2019 V-35-GR35 BEN, CIP, MOX, 
LEV 







S. aureus bacteraemia (SAB) is a condition associated with high morbidity and mortality. Patients` 
outcomes vary dependent on underlying conditions, race, age, concomitant immunosuppression, 
and type of complication, but are generally poorer in MRSA-SAB, elderly patients and patients 
treated on ICU. However, adherence to an evidence-based bundle has proven to lower case fatality 
and to improve patient outcomes. This bundle includes timely initiation of proper therapy, including 
Cefazolin and Flucloxacillin in MSSA-SAB and Vancomycin and Daptomycin in MRSA, source control, 
repeat blood cultures to document bloodstream clearance, active exclusion of secondary foci, clinical 
re-evaluation, and defined durations of therapy.  
Our study aimed to investigate the extent of adherence to the acknowledged SAB bundle in MSSA-
SAB patients. An Antibiotic Stewardship (ABS) program was in place during the whole study period 
(June 2016 – June 2018) consisting of ABS ward rounds mainly on the ICUs and the designated septic 
surgery wards. ID consultations for SAB were available, but optional. Communication of the 
constituents of the SAB bundle took place predominantly through active calls by the medical 
microbiologist and a summary of the SAB bundle given out on the laboratory report. 
 
1. Adherence to the SAB care bundle 
Follow-up blood cultures (FUBC) 
Taking follow-up blood cultures (FUBC) after initiating adequate antimicrobial therapy is necessary to 
document proper response to treatment and to assess the likelihood of complications. Persistent 
SAB >72h duration requires prolonged treatment and is a strong indicator of complication. SAB 
management guidelines advise to take FUBC at days 2–4 d after the initial set but do not specify the 
number of blood culture pairs that should be sampled. Data suggest that in case of S. aureus 
sensitivity of a single blood culture pair is ~90%, albeit sensitivity differs from initial inoculum and 
thus from underlying conditions (catheter-associated SAB tending towards higher concentrations), 
consistency of bacteraemia (intermittent SAB in infective endocarditis, deep tissue abscesses), and 
antibiotic pre-treatment (A. Lee et al. 2007). There is evidence that a single negative FUBC drawn on 
days 1-3 has a lower NPV of 87%-93% for resolution of SAB, as intermittent negative BC occur in up 
to 13% of cases. Up to four blood cultures are needed in order to exceed 99% detection rates 
(Stewart et al. 2019).  
In our setting, FUBC were taken in 61,6% of patients only. Most of our cohort received a sampling of 
1-2 bottle pairs per sampling point. 67,2% of FUBC were sterile at the first sampling point. However, 
intermittent negative FUBC occurred in 5,6% and there might be a lack of sensitivity in patients 
where one to two bottle pairs are collected per sampling date. The median time from index BC to 
FUBC was 5 days (IQR 3-7 days). Practically that means FUBC were drawn 2-3 days after detection of 
S. aureus, but in half of the cases 5 or more days later. Summarizing the evidence given above 
sampling of FUBC should be restructured with emphasis on drawing three bottle pairs at days 2-4 of 
targeted treatment. FUBC sampling should be demanded for all patients with SAB. Timing of FUBC 
needs to be optimized in half of the cases. 
Empiric and targeted therapy 
93.47% of patients received empiric antibiotic treatment, in 90% the drug chosen had in vitro activity 
against the S. aureus strain found. The prevailing class prescribed were ß-lactam/ ß-lactamase 
inhibitor combinations in 49.5% of regimens (31.25% received Piperacillin/ Tazobactam, 18.25% 
received Ampicillin/ Sulbactam, either alone or in combination with MLS class or quinolones). This is 
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consistent with the indications that led to empiric treatment in most cases (inflammatory 
constellation with unknown focus, SSTI, HAP and CAP) and recommendations given in our in-house 
anti-infective guidelines. Risk for 90-days-death was increased two-fold (p<0.001) in patients 
receiving an empiric treatment with a ß-lactam-/ ß-lactamase inhibitor combination. This effect may 
be due to the underlying condition that led to the empiric therapy. Patients with admission due to 
SSTI are treated predominantly with Clindamycin or quinolones and have a better outcome 
compared to patients presenting with septic shock or inflammatory constellation with unknown 
focus who receive Piperacillin/ Tazobactam or patients with severe pneumonia receiving Ampicillin/ 
Sulbactam plus Azithromycin or Clarithromycin. On the other side, although ß-lactam-/ ß-lactamase 
inhibitor combinations like Piperacillin/Tazobactam have documented excellent in vitro serum 
bactericidal activity against S. aureus (Lemmen et al. 2004), clinical outcomes using such 
combinations may be unsatisfactory and are inferior to Cefazolin and Flucloxacillin regimens in terms 
of bloodstream clearance and mortality  (Van Hal, Jensen, and Vaska 2012, (Beganovic et al. 2019). In 
SAB, empiric use of Piperacillin/Tazobactam as well as empiric use of cephalosporins (9.1% in our 
study) has been reported to increase 30-day mortality compared to patients receiving cloxacillin or 
cefazolin (Van Hal, Jensen, and Vaska 2012; Paul et al. 2011). This may in case of ß-lactam-/ 
ß-lactamase inhibitor combinations be due to the presence of blaZ ß-lactamases, especially type C 
blaZ, which confer a marked inoculum effect when exposed to Ampicillin/Sulbactam and 
Piperacillin/Tazobactam (Kyoung-Ho Song et al. 2019). The increased mortality with Piperacillin/ 
Tazobactam has been described in previous studies (Beganovic et al., 2019, Paul et al. 2011).  
An early likelihood-assessment of underlying SAB could lead to earlier initiation of a targeted 
treatment. Except estimating the risk of SAB due to underlying risk factors like dependence on 
haemodialysis, intravenous drug abuse or clinical presentation suggesting the presence of SSTI or 
spondylodiscitis, there is no clinical risk score established. Microbiological suspicion of S. aureus 
whenever Gram-positive cocci in clusters are seen in direct microscopy of sputum samples 
dominating the picture, Gram-positive cocci in clusters in intraoperative swabs in case of SSI or 
prosthetic device could already emphasize the addition of Cefazolin or Flucloxacillin to the empiric 
regimen in case patients are proven not to be MRSA carriers. A recent systematic review concluded 
that detection of Gram-positive cocci in clusters in respiratory samples of patients with VAP has the 
potential to refine risk assessment for the presence of S. aureus (Ranzani et al. 2020). As our data 
showed that especially in cases of CAP pneumonia was also the focus of SAB, early feedback of a 
microscopy suggestive for the presence S. aureus could turn out beneficial for an early switch from a 
β-lactam-/ β-lactamase inhibitor formulation. The predictive values of an indicative microscopy in 
CAP and the effect of an early switch still have to be determined. 
Previous microbiological results should be taken into account as well: Our data show than many 
patients are either long-term colonized with S.  aureus at different body sites or experience more 
than one episode of SAB in short time frames (median time 38 days, IQR 4-209).  
Another option would be risk assessment through MSSA screening in parallel to the established 
MRSA screening. It is known that S. aureus colonisation is associated with development of 
bloodstream infection, with most colonizing and infecting strains being identical by pulsed-field gel 
electrophoresis (PFGE) (Marshall and McBryde 2014). As shown in a study from 2004, nosocomial 
S. aureus bacteraemia was three times more frequent in S. aureus carriers (1,2%) than in non-carriers 
(0.4%; relative risk 3.0) and 80% of strains causing bacteraemia in carriers were endogenous 
(Wertheim et al. 2004). Additive culture screening for MSSA in parallel to MRSA screening should 
cover nose, throat, axilla, groin and rectum to achieve good sensitivity (Marshall and McBryde 2014). 
Knowing the patient`s carrier status could help to initiate precise empiric therapy as it is already 
done in MRSA carriers.  
Further studies are needed to clarify whether a “search-and-target”-strategy consisting of a wider or 
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subgroup-specific MSSA screening would improve treatment outcomes in patients with SAB and 
assess cost-effectiveness of this approach. 
Examining the antibiotic therapy given we often could observe an erratic mode of choosing, 
combining, and switching antimicrobials for treatment. Reasons for changing regimens were not 
documented in most cases of paper-based health records and were not evidently due to allergy, 
nephro- or hepatotoxicity. This unstructured mode of administering antimicrobials predominantly 
took place on non-ICU wards. Here, mandatory ID specialist consultations with documentation of 
recommended drug, dose and approximated length of therapy and follow-up of patients could help 
synchronizing antibiotic prescription and prevent too short, under-dosed regimens leading to 
selection and induction of resistant bacteria. 
Interestingly, survival rates did not differ between groups either receiving Flucloxacillin or Cefazolin 
or receiving any other antibiotic regimen. A similar percentage of patients treated on ICU and 
patients on normal wards received these substances. Comparing co-morbidities and, whenever 
available, SAPS (mortality assessment) and SOFA (morbidity score) scores, distributions in both 
groups were remarkably similar. Thus, a comparable outcome in the non-Flucloxacillin/ Cefazolin 
group should not be due to an a priori better general state of health in these patients. Proper dosing 
and length of therapy with Cefazolin/ Flucloxacillin did not influence survival as well. Underdosing of 
Flucloxacillin from today`s point of view was due to the outdated in-house guideline valid from 2014-
2016, where in cases of moderate to severe kidney failure a dosage of 3x1,5g was recommended. 
This dosing scheme was changed and implemented stepwise from 2017 on with some latency. 
However, increasing the dose did not show to affect survival. The median time from initiation of an 
empiric therapy to step-down to Flucloxacillin/ Cefazolin was 3 days (IQR 1-4), indicating a rapid de-
escalation in most cases. Anyway, Cox regression analysis did not show an impact on survival based 
on timing of targeted therapy.  As mentioned before, targeted treatment with Cefazolin or 
Flucloxacillin sometimes was combined with parallel, sometimes single-time administration of other 
substances (e.g., Clindamycin or Linezolid), which does not allow for clear comparison between the 
groups and may influence the lacking evidence of superiority of Cefazolin or Flucloxacillin in terms of 
survival.  
Regarding the choice of drug, clean data to compare FLU/ CZO treatment with other mono- or 
combination therapies in MSSA bacteraemia (e.g., 3rd generation cephalosporins, fluoroquinolones, 
MLS group antibiotics or other drugs like Fosfomycin, Linezolid, or Rifampicin) are limited. 
Presumably, timely and targeted source control plus the influences of underlying severity of disease 
and immune response of the patient are more important than the precise antibiotic initiated if there 
is in vitro efficacy against S. aureus and a justifiable PK/PD profile for the individual complication 
treated. On the other side, both Flucloxacillin and Cefazolin exhibit an overall favourable safety 
profile and, due to their narrow spectrum and a low selection of antibiotic resistance, should remain 
the gold standard of treatment. 
Duration of therapy 
Median durations were adequate for the underlying complications, on the other side that means that 
half of the patients in each group received shortened courses compared to consensus 
recommendations. However, this may not have an overall treatment effect as in many cases 
recommended treatment durations are based on low-grade evidence only (e.g., treatment durations 
for endocarditis, spondylodiscitis, implant infection) and again, emphasis should be made on source 
control. 
Recent data suggest, that treatment courses <14 days even in uncomplicated SAB are more often 
prone to relapse or recurrent infection and therefore should not be encouraged (Chong et al. 2013). 
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However, in our sample set no difference was evident between the short and long treatment groups 
regarding the probability of relapse, albeit median days to relapse tended towards shorter time 
spans in the short-course group. The effect might be obscured due to censored data as patients were 
not followed up actively but only based on electronic health records during readmissions to our 
hospital. 
Source control: CVC 
Here, our evaluation was consistent with prior reports: Removal of a pre-existing central venous line 
was associated with significantly increased survival (p=0.004). This again demonstrates the utmost 
importance of source control. 
Diagnostic work-up/ Exclusion of foci 
Diagnostic work-up of SAB should include active search for secondary foci by means of imaging and 
exclusion of infective endocarditis with TTE or TOE.  
Roughly, 5–15% of patients with SAB have or will develop IE (Kern 2010), so in every patient with SAB 
the bacteraemia can be either the precursor or the sign of IE. Within the first days of bacteraemia, 
TEE should be performed to rule out IE as a cause of bacteraemia, at later time points TEE it is used 
to rule out IE as a secondary metastatic complication of SAB. Recommended for all patients with SAB 
due to substantially higher sensitivity compared to TTE (Fowler et al. 1997) no precise information is 
provided about timing in initial assessment or as a follow-up measure complicated courses with 
prolonged bacteraemia. As 90% of patients with SAB do not initially present with IE, data suggest 
that sensitivity of echocardiography is highest at a later time point (5–7 days) with repeat study in 
high-suspicion cases (Allon 2009). In our cohort, TTE was performed in 64.3% TEE in 40.5% only. 
Costs, feasibility considering the patient`s underlying condition, and risks are probably the prominent 
factors to explain the low percentage of TEEs performed.  
Imaging techniques were performed in approximately two thirds of patients (CT-Scans in 76.5%, but 
PET-CT scans in 17.9% only), probably due to mild clinical presentations suggesting uncomplicated 
courses. Whether clinical assessment has been performed properly is not evaluable due to the 
retrospective nature of our investigation. 
Adherence to the core components of the bundle 
Adherence to the core components of the S. aureus bundle did not influence survival or relapse rate. 
This finding came as a surprise as there is substantial contrary evidence from the literature (Kimmig 
et al. 2018; Arensman et al. 2020; López-Cortés et al. 2013; Lines et al. 2020) (Vogel et al. 2016).  
The question arises which influenceable factors are crucial in preventing mortality rates. From an 
infectiological point of view, timely source control, an empirical therapy that has in vitro activity 
against the causative strains and a fast de-escalation to a suitable targeted therapy are most likely to 
alter outcomes. Both empirical and targeted treatment should consist of drugs with a favourable 
safety profile. However, detailed information about substances used, dosing, and availability and 
peculiarities of local guidelines are reported inconsistently in studies, making it hard to assess and 
compare the effect of these variables.  
As in our setting the empiric administration of ß-lactam/ ß-lactamase inhibitor combinations is 
common (49.5% of empiric regimens in our cohort) and was significantly associated with a higher 
mortality rate, impacts of bundle adherence and targeted antibiotic therapy may be diluted due to 
early influences of this regimen or hidden confounders.  
In most studies on the impacts of bundle adherence, cases of MRSA-SAB and MSSA-SAB are 
evaluated collectively. However, it is known that mortality in MRSA-SAB is higher, probably due to a 
higher virulence of strains as well as delayed onset, toxicity, and probably lower efficacy of 
bloodstream clearance of Vancomycin (Van Hal, Jensen, and Vaska 2012). ABS efforts improving 
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timely and proper administration of Vancomycin or Daptomycin could play a major role in improving 
outcomes in populations with a high percentage of MRSA-SAB, at the same time leading to an 
overestimation of bundle adherence effects in MSSA-SAB. The proportion of MRSA-SAB differs widely 
between studies, ranging from 17-18% (Robinson et al. 2012; Bai et al. 2015), 32-35% (Fowler et al. 
1998; Brigg Turner et al. 2016), to 54% (Honda et al. 2010). The therapeutic options available during 
the study periods (from Vancomycin only to Linezolid and Daptomycin) and dosing schemes changed 
with time, making it harder to compare earlier and later studies. In our 13 patients with MRSA-SAB, 
the strains were empirically covered in 46.2% only, highlighting the importance of rapid introduction 
of appropriate targeted treatment in this group of patients.  
We did not include source control into the core component setup as in patients with a distinct focus 
(spondylodiscitis, SSTI) surgical intervention or drainage were performed routinely. A study from 
2003 (Kim et al. 2003) found that the presence of noneradicable foci (“unknown primary site, 
pneumonia, endocarditis, and osteomyelitis or arthritis”) was an independent predictor of mortality. 
Moreover, “the difference in mortality between inappropriate empirical antibiotic therapy (6 [12.5%] 
of 48) and appropriate empirical antibiotic therapy (5 [10.4%] of 48) in patients with eradicable foci 
was not significant (OR, 1.23; 95% CI, 0.35–4.33)”. The results of this study undermine that not only 
source control, but the presence of an eradicable focus itself has an impact on prognosis and 
outcome. Referring to our study population, where no primary focus could be found in 61.9% of 
patients and a secondary focus was present in less than 13% of patients, the predominance of 
patients with “non-eradicable” foci may have been an important influence upon mortality. 
There are, however, also studies failing to demonstrate significant effects upon survival, treatment 
success, and relapse despite showing a significantly improved quality care bundle adherence (Jenkins 
et al. 2008; Brigg Turner et al. 2016; Arensman et al. 2020). Improving appropriateness of antibiotic 
treatment and increasing awareness for the detection of complications may have protective effects 
that are difficult to objectify (e.g., collateral damage to the microbiota, antibiotic selection pressure, 
attributable toxicities, Clostridioides infections, chronification of complications). A recent large 
multicenter cohort study including 31,002 patients with S. aureus bacteremia came to the conclusion 
that “having an ID consultation during the index hospital stay […] was associated with improved 
postdischarge outcomes for at least 5 years, suggesting that contributions of ID specialists to 
management during acute infection may have a substantial influence on long-term outcomes” (Goto 
et al. 2020). 
 
2. Typing of strains 
Comparing the gross composition of our cohort regarding median age (67 years, IQR 56-78), mode of 
acquisition (hospital-acquired 44.3%) and all-cause death <14 days after SAB (16.8%), our data are 
highly congruent with a lager European study assessing temporal trends in spa types 
(Grundmann et al. 2014). The spa type per isolate ratio in this paper was 0.23, in our study the ratio 
was 0.48, meaning a higher diversity in spa types. Comparing the top 10 ranking of spa types in 
MSSA, in our study the 3rd ranking t608 (the predominant spa type in bacteraemia without any 
complications) was not present in the European top 10, the remaining ranks included the same spa 
types in mixed order. In the European context t032 was the most frequent spa type amongst MRSA 
with 17.9%, in our study three isolates out of thirteen (23.07%) had the same spa type. Comparing 
the top 10 ranking, our MRSA isolates comprised other spa types, indicating differences in local 
epidemiology. Interestingly, spa type t002 dominated in CA-SAB and was present much less 
frequently in HCA- and HA-SAB. Comparing our findings to other European publications, t002, t008 
and t084 seem to consistently occupy the leading ranks. In our study, we also found the 
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representative of an emerging MSSA lineage in Europe, S. aureus of spa type t571, which was 
assigned to spa CC 015. Spa type t571 is described as being livestock-associated in case of MSSA and 
belongs to the MLST-derived CC398. It has reportedly been described to cause severe infections 
(Bonnet et al. 2018; Vandendriessche et al. 2011). A previous study described t571 as being still rare 
in Germany amongst strains causing infections (0.46% of investigated blood culture isolates) (Cuny et 
al. 2013). In our study, t571 isolated were MSSA and thus probably livestock-associated and 
accounted for 1.72% of 291 primary isolates (rank 11). Three out of five strains were Erythromycin 
resistant, probably mediated by ermT as described before (Cuny et al. 2013). 
Patients with no (actively excluded) complication tended to have a different ranking of spa types 
with spa type t008 dominating in all complication groups, whereas spa type t608 has been 
significantly associated with an uncomplicated course. Besides that, no other associations between 
spa types or spa CCs and clinical manifestation, onset or mortality could be proven. This is contrary 
to other studies indicating an association between spa type/ CC and strain virulence and 
pathogenicity (Aamot, Blomfeldt, and Eskesen 2012; Nienaber et al. 2011). In order to create rapid 
diagnostic tools to predict primary or secondary sources of bacteraemia and to discriminate 
uncomplicated from complicated courses, further studies are needed. A study published in 2018 
(Pérez-Montarelo et al. 2018) found “pathogen-related molecular markers significantly associated 
with a specific source of bacteraemia” which “included the presence of sea, undisrupted hlb and isaB 
genes with catheter-related bacteraemia; sed, splE, and fib genes with endocarditis; undisrupted hlb 
with skin and soft tissue infections; and finally, CC5, msrA resistance gene and hla gene with 
osteoarticular source”. Other possibilities could be correlational transcriptome studies or 
comparative proteomics in search for predictive markers of outcome. Currently, there are MS-based 
approaches being refined for shotgun proteomics of biological samples. Advantages of an MS-based 
proteomic approach are simple and fast sample preparation and a sensitive, fast, quantitative and 
qualitative direct imaging of active components of the cell. Maldi-ToF is already being used in 
predicting antibiotic susceptibility profiles or virulence in designated microorganisms (Flores-Treviño 
et al. 2019; Burckhardt and Zimmermann 2018; Liu and Schey 2005; Schubert et al.).  
The implementation of the “whole package” consisting of species identification, prediction of 
resistance patterns and virulence would combine accuracy, speed, and cost-effectiveness with the 
advantage of most laboratories already being familiar with the application and interpretation of the 
Maldi-ToF technique. 
However, the course of an infection is always determined by the pathogenicity of the infectious 
agent, the response of the host`s innate as well as adaptive immune response and pre-existing 
vulnerable sites inside the body that facilitate certain courses of disease. Whereas the presence of 
implanted devices is a well-known risk factor for development of secondary metastatic foci, in some 
cases like spondylodiscitis it remains elusive why this complication is present in some patients only. 
That said, the search of a rapid and sensitive diagnostic marker in the infecting strain to predict the 
course of SAB is surely an incomplete and simplified approach. Although there are some studies 
exploring human immune marker for distinguishing uncomplicated from complicated courses 
(e.g., the study by Rasmussen and colleagues (Rasmussen et al. 2017), where weaker HLA-DRA and 
CD74 expression was correlated with a complicated course of SAB), the impact of each the innate 
and adaptive immune response in the course and complications of SAB has still to be determined.  
Investigating cases of HA-SAB, cgMLST detected three clusters consisting of two strains each 
indicating invasive infection after clonal cross-transmission. The first cluster most likely included two 
cases of CA-SAB in which blood cultures have been drawn with some latency to the true onset. For 
the latter two clusters, cross-transmission via personnel would be a probable explanation 
(Bloemendaal et al. 2009, Grundmann et al. 2005, Price et al. 2017). Previous studies reported that 
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up to 40% of S. aureus acquisitions on ICU are due to patient-to-patient cross-transmission 
(Bloemendaal ALA, et al.). However, in our hospital no routine screening for MSSA carriage takes 
place in patients or personnel. Thus, the true dimension of cross-transmission and the proportion of 
transmission to ultimately invasive infection in our setting remains elusive. Additionally, due to 
financial reasons cases of CA-SAB were not included in the analysis, although hospitalized patients 
with CA-SAB could serve as a reservoir for transmission. Whether screening and eradication of 
S. aureus carriage would show a significant benefit in preventing SAB opposed to the efforts and 
costs of diagnostic and preventive procedures is unclear. Probably a benefit could be seen in certain 
high-risk populations only (e.g., long-term stay at the Intensive Care Units). For approximation to this 
this question, further studies are needed. 
 
3. Limitations 
The limitations of our study are defined by its retrospective observational nature. The necessity to 
rely on and to interpret information in partly paper-based patient`s health records and working with 
arbitrary case definitions limit the comparability and reliability of data. Assessment of complications, 
mortality and relapse were restricted to patients that were treated in and readmitted to our hospital; 
thus, information may be incomplete. The effect of bundle adherence upon long-term outcomes may 
be underestimated due to the restricted follow-up time. The overall sample size of 291 cases may be 
statistically underpowered to reliably answer a subset of questions, particularly considering the 
subgroup analyses with preselected patients (e.g., the group of patients with bundle adherence 
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From June 2017 to June 2019, 291 cases of Staphylococcus aureus bacteraemia (SAB) were evaluated 
retrospectively. Patient baseline characteristics, clinical presentations, empiric and targeted 
treatment, and clinical outcomes were assessed. Our study aimed to evaluate the adherence to a 
designated SAB care bundle and to assess whether proper adherence improved patient survival. 
Furthermore, as data for spa type distributions in MSSA-SAB are scarce for Germany, we aimed to 
describe circulating spa types and spa Clonal Complexes (spa CC) in our epidemiological setting.  
Outcomes: 
Incidence density rate for 30-days mortality was 0.96/ 1,000 patient-days (pd), incidence density rate 
for 90-days mortality was 1.14/ 1,000 pd. Leading complications of SAB were sepsis (56.7%), implant 
infection (12.7%) and spondylodiscitis (12.4%). 212 patients (72.8%) had at least one complication 
including sepsis. Median time to death was 12 days (IQR 4-26.3). Sepsis (p <0.001) and age >65 
(p=0.001) significantly increased 30- and 90-days mortality. Total incidence density rate of relapse 




Resistance patterns and typing of strains: 
No unusual resistance patterns were found. MRSA-SAB occurred in 13 patients (4.4%). 35.4% of 
strains were resistant to Penicillin only, the majority of strains (32.6%) was pan-susceptible. 
141 different spa types were determined. The spa type per isolate ratio was 0.48, meaning a high 
diversity in spa types. Predominant spa types in all primary isolates were t008 (7.2%), t091 (6.5%), 
t608 (5.9%), t002 and t012 (both 4.5%), and t015 (2.4%). Patients with uncomplicated course tended 
to have a different ranking of spa types with spa type t608 leading (p=0.001) compared to patients 
with any sort of complication, where t008 was dominating (not statistically significant). 
To predict the clonal relatedness of S. aureus isolates, a grouping algorithm called BURP was used to 
cluster closely related spa types. BURP grouping resulted in 15 spa CCs, 15 singletons, and 13 
excluded spa types. Ranks 1-10 contained 81.8% of the 291 primary isolates. Predominant spa CC 
were spa CC 084/346 (19.6% of primary isolates), spa CC 790 (18.2%), spa CC 015 (12.7%), spa CC 012 
(9.3%), spa CC 002 and spa CC 008/024 (5.2% each). 
There was no statistically significant correlation between the top 7 ranking spa CCs and 30-days/ 90-
days all-cause mortality (p30d = 0.59 and p90d = 0.61), onset of SAB or type of complication.  
To predict sources and outcomes of SAB, further models are needed. Predictive models could be 
based upon detection of designated virulence factors, correlational transcriptome studies, 
comparative proteomics, or investigation of peculiarities in the regulation of host immune response 
in search for predictive markers of source and outcome. 
Investigating cases of HA-SAB, cgMLST detected three clusters consisting of two strains each 
indicating invasive infection after clonal nosocomial cross-transmission. 
Adherence to the SAB care bundle and evaluation of antimicrobial therapy: 
Overall adherence to the core components of the SAB care bundle was 18.21% only and should be 
improved by providing mandatory bed-side ID specialist or medical microbiologist consultations. 
Emphasis should be put on proper amount and timing of follow-up blood culture sampling as an 
important prospective and diagnostic measure and adequate treatment in consideration of the 
underlying condition of the patient. Given advice should be immediately documented in the health 
record or substantiated by a print checklist for cases where documentation is paper based.  
The major obstacle in surviving SAB was surviving the first two weeks: All-cause mortality was 16.5% 
up to 14 days after onset of SAB. In these rapidly fatal courses, the impact of the components of the 
SAB bundle is hard to determine and their value uncertain.  
Neither 30-day/ 90-days all-cause mortality nor likelihood of relapse were significantly influenced by 
adherence to the core components of the SAB care bundle (initiation of Cefazolin or Flucloxacillin, 
performing follow-up blood cultures, exclusion of infective endocarditis as a minimum of secondary 
focus exclusion and to administer 16-30 days of antibiotic treatment). The same applied to the single 
components of selected targeted antibiotic and the total duration of therapy. An exception was the 
unfavourable outcome in patients receiving a β-lactam-/β-lactamase inhibitor formulation 
(Piperacillin/ Tazobactam or Ampicillin/Sulbactam) as empiric treatment. In those patients, risk of 90-
days death was increased twofold compared to patients receiving any other empiric treatment. Thus, 
patients being at higher risk of invasive S. aureus infection could probably benefit from an earlier 
initiation of a targeted Flucloxacillin/ Cefazolin therapy. Despite the non-superiority against other 
treatment regimens, these substances should remain the gold standard of treatment due to their 
favourable safety profiles and narrow spectrum. However, in situations where longer oral 
consolidation treatment appears to be necessary or intravenous treatment is not possible, other 
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